



Scientific Committee on Consumer Safety

SCCS

OPINION ON
deoxyarbutin
Tetrahydropyranyloxy Phenol

The SCCS adopted this opinion at its 10th plenary meeting
on 25 June 2015

About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

They are: the Scientific Committee on Consumer Safety (SCCS), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCCS

The Committee shall provide opinions on questions concerning all types of health and safety risks (notably chemical, biological, mechanical and other physical risks) of non-food consumer products (for example: cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products such as detergents, etc.) and services (for example: tattooing, artificial sun tanning, etc.).

Scientific Committee members

Ulrike Bernauer, Qasim Chaudhry, Pieter Coenraads, Gisela Degen, Maria Dusinska, Werner Lilienblum, Elsa Nielsen, Thomas Platzek, Suresh Chandra Rastogi, Christophe Rousselle, Jan van Benthem

Contact

European Commission
Health & Food Safety
Directorate C: Public Health
Unit C2 – Health Information/ Secretariat of the Scientific Committee
Office: HTC 03/073
L-2920 Luxembourg
SANTE-C2-SCCS@ec.europa.eu

© European Union, 2015
ISSN 1831-4767
Doi:10.2875/293523

ISBN 978-92-79-56126-9
EW-AQ-16-003-EN-N

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm

ACKNOWLEDGMENTSSCCS Members

Dr. U. Bernauer
Dr. Q. Chaudhry
Prof. P.J. Coenraads
Prof. G. Degen (chairperson and rapporteur)
Dr. M. Dusinska
Dr. W. Lilienblum
Dr. E. Nielsen
Prof. T. Platzek
Dr. S. Ch. Rastogi
Dr. Ch. Rousselle
Dr. J. van Benthem

Former SCCS Member

Prof. A. Luch

External experts

Prof. A. Bernard
Prof. J. Duus-Johansen
Dr. J. Ezendam
Prof. A. M. Giménez-Arnau
Dr. E. Mikova
Dr. E. Panteri
Prof. T. Vanhaecke

Keywords: SCCS, scientific opinion, deoxyarbutin, Tetrahydropyranyloxy Phenol, Regulation 1223/2009, CAS 53936-56-4

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on desoxyarbutin - Tetrahydropyranyloxy Phenol, 25 June 2015, SCCS/1554/15

TABLE OF CONTENTS

ACKNOWLEDGMENTS	3
TABLE OF CONTENTS.....	4
1. BACKGROUND	5
2. TERMS OF REFERENCE.....	5
3. OPINION.....	6
3.1 Chemical and Physical Specifications.....	7
3.1.1 Chemical identity	7
3.1.2 Physical form	8
3.1.3 Molecular weight	8
3.1.4 Purity, composition and substance codes.....	8
3.1.5 Impurities / accompanying contaminants	8
3.1.6 Solubility	8
3.1.7 Partition coefficient (Log P _{ow}).....	9
3.1.8 Additional physical and chemical specifications.....	9
3.1.9 Homogeneity and Stability	9
3.1.10 Characterization of desoxyarbutin used in current toxicity studies ..	11
3.2 Function and uses.....	11
3.3 Toxicological Evaluation	12
3.3.1 Acute toxicity	12
3.3.2 Irritation and corrosivity	14
3.3.3 Skin sensitisation.....	17
3.3.4 Dermal / percutaneous absorption.....	19
3.3.5 Repeated dose toxicity	22
3.3.6 Mutagenicity / Genotoxicity	26
3.3.7 Carcinogenicity.....	32
3.3.8 Reproductive toxicity.....	32
3.3.9 Toxicokinetics and metabolism.....	32
3.3.10 Photo-induced toxicity	34
3.3.11 Human data.....	36
3.3.12 Special investigations	38
3.3.13 Information on the toxicity of hydroquinone	38
3.3.14 Safety evaluation (including calculation of the Margin of Safety) ..	40
3.4 Discussion	42
4. CONCLUSION	45
5. MINORITY OPINION.....	45
6. REFERENCES.....	45

1. BACKGROUND

Deoxyarbutin CAS n. 53936-56-4 (4-[(tetrahydro-2H-pyran-2-yl)oxy]phenol) with INCI name Tetrahydropyranyloxy Phenol is a skin lightening agent synthesised through removal of hydroxyl groups from the glucose side-chain of β -arbutin.

In the first opinion (SCCP/1158/08) on β -arbutin adopted on 15th April 2008 the SCCP raised concerns with other substances resulting in the release and/or formation of hydroquinone.

However, Hydroquinone (CAS 123-31-9) is listed in Annex II/1339 of the Cosmetic Regulation No 1223/2009; therefore it is banned as cosmetic ingredient with the exception of entry 14 in Annex III. It is only permitted for professional use in artificial nail systems in a concentration in the final product up to 0.02%. Since Hydroquinone could not be used as a skin whitener after introduction of a ban, other substances have been used for that purpose, including Arbutin.

A dossier on the related substance, deoxyarbutin, was submitted to the European Commission by Girindius AG in 2008.

2. TERMS OF REFERENCE

- (1) Does the SCCS consider on the basis of the provided scientific data, the use of deoxyarbutin to be safe for consumers in cosmetic products in a concentration up to 3% in face creams?*
- (2) Does the SCCS have any further scientific concerns with regard to the use of deoxyarbutin in cosmetic products?*

3. OPINION

Introduction

Deoxyarbutin (4-[(tetrahydro-2H-pyran-2-yl)oxy]phenol) is a skin lightening agent synthesised through removal of hydroxyl groups from the glucose side-chain of β -arbutin.

In January 2012 the SCCS sent out a "Request for additional data on arbutin and its derivatives" to companies who had previously submitted a dossier on such agents. Whilst applicants for the other skin lightening agents (alpha- and beta-arbutin) responded, the mail to the applicant for deoxyarbutin, Girindius AG (Germany) was returned to sender.

A search revealed that the company has gone out of business (bought by Nicco Denco Avecia, which was then acquired by Merck & Co.).

This Opinion is based on the original submission of 2008 by Girindius AG.

Note: „Deoxyarbutin 100“=code for the company's compound name

Overview on Studies conducted

Studies were generally carried out to the appropriate OECD/SCCP guidelines and to GLP. Where this was not the case, as in some very early studies, the rationale for their inclusion is stated.

Study	Test material batch/lot code	Test Guidelines	GLP	Ref.
Acute toxicity				
Acute Oral Toxicity Study with Rats (2005)	Deoxyarbutin 100/504007	OECD 423	Yes	4
Acute Oral Toxicity Study with Rats (1994)	Deoxyarbutin 100/HT0059.01	Comparable to OECD 425	Yes	33
Acute Oral Toxicity Study with Rats (1994)	Deoxyarbutin 100/HT0059.04	Comparable to OECD 425	Yes	34
Acute Dermal Toxicity Study with Rats (2005)	Deoxyarbutin 100/504007	OECD 402	Yes	5
Acute Dermal Toxicity Study with Rats (1994)	Deoxyarbutin 100/HT0059.01	Comparable to OECD 402	Yes	35
Acute Intraperitoneal Toxicity Study with Rats (1994)	Deoxyarbutin 100/HT0059.01	-	Yes	36
Skin irritation In Vitro Skin Corrosion Study – Transcutaneous Electrical Resistance Test (2005)	Deoxyarbutin 100/501002	OECD 430	Yes	6
Skin irritation Acute Dermal Irritation/Corrosion Study with Rabbits (2005)	Deoxyarbutin 100/504007	OECD 404	Yes	7
Eye irritation Acute Eye Irritation/Corrosion Study with Rabbits (2005)	Deoxyarbutin 100/504007	OECD 405	Yes	8
Eye irritation Acute Eye Irritation Study with Rabbits (1994)	Deoxyarbutin 100/HT0061.01	Comparable to OECD 405	Yes	37
Skin sensitization Local Lymph Node Assay (2005)	Deoxyarbutin 100/504007	OECD 429	Yes	9
Skin sensitization Skin Sensitization Study (LLNA)(1994) Dermal / Percutaneous Absorption	Deoxyarbutin 100/HT0059.01	Comparable to OECD 429	Yes	38
Repeated dose toxicity 28-Day Oral Toxicity Study with Rats (2006)	Deoxyarbutin 100/504007	OECD 407	Yes	18
28/91-day Percutaneous	Deoxyarbutin	-	Yes	40

Opinion on desoxyarbutin - Tetrahydropyranyloxy Phenol

Toxicity (1994)	100/HT0059.01			
Mutagenicity / Genotoxicity: <i>in vitro</i> Ames test (1994)	Deoxyarbutin 100/HT0059.01	Comparable to OECD 471	Yes	41
<i>In Vitro</i> Mammalian Cytogenetic Study (2006)	Deoxyarbutin 100/504007	OECD 473	Yes	19
Mutagenicity / Genotoxicity: <i>in vivo</i> Micronucleus Test with Mice (oral application) (2006)	Deoxyarbutin 100/504007	OECD 474	Yes	21
Micronucleus Test with Mice (oral application) (2006)	Deoxyarbutin 100/509014	OECD 474	Yes	20
Mammalian Erythrocyte Micronucleus Test (intraperito- neal application) (2007)	Deoxyarbutin 100/509014	OECD 474	Yes	21
Spermatogonial chromosomal aberration test	Deoxyarbutin 100/509014	OECD 483	Yes	25
Toxicokinetics Preliminary Penetration and Metabolism Study in Guinea Pigs (1994)	Deoxyarbutin 100/PBK 10082	-	Yes	1, 39
Photo-induced toxicity Photoirritation/Photoallergy in Guinea Pigs (1996)	Deoxyarbutin 100 / HT0059.05	-	GLP	43
Human Data Repeated Insult Patch test (2007)	SC23 (Deoxyarbutin 100) / 104544	-	GLP	24
Repeated Insult Patch test (1995)	Deoxyarbutin 100 / HT0072.01	-	GLP	42

3.1 Chemical and Physical Specifications

3.1.1 Chemical identity

3.1.1.1 Primary name and/or INCI name

INCI Name: Tetrahydropyranyloxy Phenol

3.1.1.2 Chemical names

(4-Tetrahydro-pyran-2-yloxy)-phenol


3.1.1.3 Trade names and abbreviations

deoxyArbutin; "Deoxyarbutin" 100

3.1.1.4 CAS / EC number

CAS No: 53936-56-4

EC: not available

3.1.1.5 Structural formula

Reference 17

3.1.1.6 Empirical formulaEmpirical Formula: C₁₁H₁₄O₃**3.1.2 Physical form**

White to off-white solid substance

3.1.3 Molecular weight

Molecular weight: 194.23 g/mol

3.1.4 Purity, composition and substance codes

Purity: ≥99.0 % (area)

Ref.: 17, 22, 28

3.1.5 Impurities / accompanying contaminants

Hydroquinone (290 nm)	≤0.05 % (w/w)
Benzoquinone (246 nm)	≤0.05 % (w/w)
Sum Hydroquinone and Benzoquinone	≤0.1 % (w/w)
NS 392 A* (290 nm)	≤1.0 % (w/w)
4-Benzyloxyphenol (290 nm)	≤0.1 % (w/w)
Impurity RRT** = 1.48 (290 nm)	≤0.2 % (area)
Impurity RRT** = 2.06 (290 nm)	≤0.2 % (area)
Each unknown Impurity (290 nm)	≤0.2 % (area)

* NS 392A = 2(4-Benzyloxy-phenoxy)-tetrahydropyran

** RTT = relative retention time in HPLC

Heavy Metals:	≤20 ppm
Loss on Drying:	≤0.5 % (w/w)
Residue on Ignition:	≤0.5 %
Water Content:	≤0.5 %

Ref.: 17, 22, 28

3.1.6 Solubility

Solubility in Methanol:	667 g/L (24°C)
Solubility in Ethanol:	500 g/L (24°C)
Solubility in Acetone:	667 g/L (24°C)

Solubility in water: 1.6 g/L (20°C), 2.0 g/L (30°C) (Directive 92/69/EEC)
Ref.: 14, 22, 28

3.1.7 Partition coefficient (Log P_{ow})

Partition Coefficient (Log P_{o/w}): 2.0 (at 35°C, pH 7.0 buffered)
(Directive 92/69/EEC)

Ref.: 15

3.1.8 Additional physical and chemical specifications

Melting Point: 88.6°C
Boiling Point: 307.5 °C
Density: 1.276 at 22°C (Directive 92/69/EEC)
pKa: 10.1
Ignition Point: No self-ignition temperature was determined up to 10°C.
Not classified as "self-igniting" (Directive 92/69/EEC)
Vapour pressure: 4.3x10⁻⁴ Pa at 25 °C (experimental, Directive 92/69/EEC)
0.0137 Pa at 25°C (calculated)

Ref.: 10, 11, 12, 13, 16, 22, 28

3.1.9 Homogeneity and Stability

Stability during storage:

Data in the table below indicate that deoxyarbutin, when protected from humidity, temperatures above 8°C and light, for is stable for at least 2 years (conditions: 2-8°C, argon atmosphere, desiccant).

Test	Specification	0 months	26 months
		24.10.05	22.10.07
		Q-No. 41432	Q-No. 107960
Purity (HPLC)			
Deoxyarbutin 100 (290 nm)	≥99.0 % (area)	99.7 % (area)	99.8 % (area)
Hydroquinone (290 nm)	≤0.05 % (w/w)	0.02 % (w/w)	0.03 % (w/w)
Benzoquinone (246 nm)	≤0.05 % (w/w)	<0.01 % (w/w)	0.01 % (w/w)
Sum Hydroquinone and Benzoquinone	≤1.0 % (w/w)	< 0.1 % (w/w)	0.04 % (w/w)
NS 392 A* (290 nm)	≤0.1 % (w/w)	n.d.	0.1 % (w/w)
4-Benzyloxy phenol (290 nm)	≤0.2 % (area)	n.d.	n.d.
Impurity RRT** = 1.48 (290 nm)	≤0.2 % (area)	0.2 % (area)	n.d.
Impurity RRT** = 2.06 (290 nm)	≤0.2 % (area)	0.1 % (area)	0.1 % (area) RRT 2.17: <0,1 %

* NS 392A = 2(4-Benzyloxy-phenoxy)-tetrahydropyran ** RTT = relative retention time in HPLC

Deoxyarbutin batch 509014 was manufactured on 12 September 2005 and was stored at ambient temperature then in cold storage from 30.11.2005.

After 3 months storage at 25°C and 60% relative humidity (Table below), deoxyarbutin showed partial decomposition with an increasing hydroquinone content above the specified limit.

Opinion on desoxyarbutin - Tetrahydropyranyloxy Phenol

Batch 504007	Specification	0 months	3 months
		June 2005	September 2005
		Q-No. 96830	Q-No. 98223
Purity (HPLC)			
Deoxyarbutin 100 (290 nm)	≥99.0 % (area)	99.5 % (area)	99.1 % (area)
Hydroquinone (290 nm)	≤0.05 % (w/w)	0.02 % (w/w)	0.20 % (w/w)
Benzoquinone (246 nm)	≤0.05 % (w/w)	<0.01 % (w/w)	<0.01 % (w/w)
Sum Hydroquinone and Benzoquinone	≤0.1 % (w/w)	0.02 % (w/w)	0.2 % (w/w)
NS 392 A* (290 nm)	≤1.0 % (w/w)	0.6 % (w/w)	0.5 % (w/w)
4-Benzyloxyphenol (290 nm)	≤0.2 % (area)	n.d.	n.d.
Impurity RRT** = 1.48 (290 nm)	≤0.2 % (area)	<0.1 % (area)	<0.1 % (area)
Impurity RRT** = 2.06 (290 nm)	≤0.2 % (area)	n.d.	0.1 % (area)

* NS 392A = 2(4-Benzyloxy-phenoxy)-tetrahydropyran ** RTT = relative retention time in HPLC

Further tests on storage stability under "stress conditions" (40°C, 75% relative humidity) showed a decrease in deoxyarbutin compound (initially 99.6% to 90.3% after 3 months), and an increase in hydroquinone content from 1.67% (w/w), 2.93% (w/w) and 4.4% (w/w) after 1, 2 and 3 months, respectively.

(Reference 29)

Stability in Solution:

Aqueous solutions at pH 7 or at slightly basic conditions (pH 8) are stable. At pH 8 in solution (and with no protection against daylight), 0.03% parent compound degrades per hour, with no hydroquinone formation observed. Acidic aqueous solutions (pH <7) are not stable.

At pH 6, some decline in the content of deoxyarbutin with a corresponding increase in hydroquinone (HQ) is noted: Rate of HQ formation at pH 6 per hour is 0.02 % and at pH 5 0.2 % per hour. At pH 1 only HQ and no more deoxyarbutin is found in HPLC analysis.

Extensive exposure of deoxyarbutin to light, temperatures above >8°C and oxygen should be avoided. For analytical purposes, it is recommended to freshly prepare the test solutions at 8°C.

Stability in o/w formulation:

Cream (o/w) formulations of deoxyarbutin S/W (6%) are stable at a temperature of ≤8 °C, but somehow degrade under room temperature conditions turning from a white to a yellowish colour (see table below).

Storage conditions / Test	1 month	2 months	3 months
Storage: 2 – 8°C			
Description	white cream	white cream	white cream
Assay: Deoxyarbutin 100	5.8 % (w/w)	5.7 % (w/w)	5.7 % (w/w)
Assay: Hydroquinone	0.001 % (w/w)	0.001 % (w/w)	n.d.
Storage: ambient temperature			
Description	white cream	white cream	yellowish cream
Assay: Deoxyarbutin 100	5.7 % (w/w)	5.8 % (w/w)	5.7 % (w/w)
Assay: Hydroquinone	0.002 % (w/w)	0.004 % (w/w)	0.006 % (w/w)

(Reference: 29)

SCCS comment

The applicant reports that deoxyarbutin is stable for at least 2 years when protected from humidity, temperatures above 8°C and light. However, it has been shown that deoxyarbutin is thermolabile in aqueous solutions; this lack of stability may pose difficulties for its use in cosmetics (Yang et al., 2010). On the other hand, apparently stability can be achieved for oil in water formulations (creams) stored at low temperatures and protected from light, and in anhydrous emulsions also at higher temperatures (Lin et al., 2011).

The experiments determining the stability of deoxyarbutin look conclusive and were shown to be reproducible. It has been clearly stated that this compound and its formulations should be stored at low temperatures under exclusion of air and ambient light (storage recommendation for a lifetime of 24 months: 2-8°C, under argon atmosphere and addition of desiccant). Significant degradation occurs at pH-values lower than pH 7 (0.02% and 0.2% HQ per hour at pH 6 and 5, respectively) and above pH 7 (0.03% at pH 8) and thus under in-use conditions. It should be noted that the average pH-value of human skin is determined at approximately at pH 5.5.

3.1.10 Characterisation of deoxyarbutin used in current toxicity studies

Typical commercial batches of deoxyarbutin (batch 504007 and 509014) were used for the toxicological evaluation during the notification process. This material was characterised appropriately as summarised below.

Testing Parameter	Requirements	Batch 504007	Batch 509014
Description	white to off-white solid substance	conforms	conforms
Identity (IR)	Conforms to reference spectrum	conforms	conforms
Loss on drying	≤0.5% (w/w)	<0.1% (w/w)	0.1% (w/w)
Water content	≤0.5% (w/w)	0.1% (w/w)	0.1% (w/w)
Residue on ignition	≤0.5% (w/w)	0.1% (w/w)	0.2% (w/w)
Heavy metals	≤20 ppm	conforms	conforms
Purity (HPLC)			
Deoxyarbutin 100 (290 nm)	≥99.0 % (area)	99.5 % (area)	99.7 % (area)
Hydroquinone (290 nm)	≤0.05% (w/w)	0.02 % (w/w)	0.02 % (w/w)
Benzoquinone (246 nm)	≤0.05% (w/w)	0.01 % (w/w)	<0.01 % (w/w)
Sum of Hydroquinone and Benzoquinone	≤0.1% (w/w)	0.02 % (w/w)	<0.1% (w/w)
NS 329 A	≤1.0%	0.6 %	n.d.
4-Benzyloxyphenol (290 nm)	≤0.1% (w/w)	n.d.	n.d.
Imp. RRT 1.48 (290 nm)	≤0.2% (area)	n.d.	n.d.
Imp. RRT 2.06 (290 nm)	≤0.2% (area)	0.1% (area)	0.1% (area)
Each unknown impurity (290 nm)	≤0.2% (area)	n.d.	RRT 1.1 at 0.1% (area)

NS 392A = 2(4-Benzyloxy-phenoxy)-tetrahydropyran

RRT = relative retention time

Analysis certificates for each batch can be found in the respective reports cited in section 3.5. (Toxicological evaluation)

3.2 Function and uses

Deoxyarbutin (4-[(tetrahydro-2H-pyran-2-yl)oxy]phenol) is synthesised through removal of hydroxyl groups from the glucose side-chain of β -arbutin, another skin lightening agent. It

is an inhibitor of the enzyme tyrosinase and therefore reduces formation of melanin. Deoxyarbutin is claimed to be more effective and less cytotoxic than hydroquinone (Yang et al 2010; Chawla et al 2008; Hu et al 2009). As it does not have the β -glucoside structure, it would not be expected to be a substrate for the β -glucosidase enzymes that are found in skin bacteria and in human tissues. Since deoxyarbutin lacks the hydroxyl groups on the glucose moiety, it is expected to be more lipophilic and more easily absorbed by the skin than arbutins (alpha- or beta-arbutin).

Deoxyarbutin is intended to be used as a skin lightening active ingredient in cosmetic preparations up to a maximum concentration of 3.0% in leave-on cosmetic products.

(References: 1, 28, 30)

3.3 Toxicological Evaluation

3.3.1 Acute toxicity

3.3.1.1 Acute oral toxicity

Date of report:	August 2005
Guideline/method:	OECD 423 (2001)
Species/strain:	Rat/Sprague-Dawley (CrI:CD(SD)IGS BR)
Group size:	12 females in total (3 per experimental group)
Test substance:	deoxyarbutin
Batch:	504007
Purity:	99.5% (HPLC)
Dose levels:	300, 2000 mg/kg bw
Dose volume:	10 ml/kg bw
Vehicle:	Corn oil
Route:	oral (gavage)
Exposure:	single application
Observation period:	14 days
GLP:	Yes

The test substance was administered by oral gavage to each set of 12 female Sprague-Dawley rats in total. A stepwise approach was performed and each 3 animals received 300 mg/kg bw at step 1 and 2 as well as 2000 mg/kg bw at step 3 and 4 as an oily suspension in corn oil. The dosing volume was 10 ml/kg bw. The animals were observed for treatment-related effects within the periods 0-0.5, 0.5-1, 1-2, 2-4 and 4-6 hours after administration and then at least once a day for a total of 2 weeks. Observations included but were not limited to changes in skin, fur, eyes, the occurrence of secretions and excretions, autonomic activity, changes in gait, posture and the presence of convulsions. Bodyweights were determined prior to administration and on days 7 and 14 after application. Gross pathology was performed in rats that had died and in survivors that were sacrificed on day 14.

Results

At 300 mg/kg bw 2/6 animals showed clinical signs of reduced well-being, while at 2000 mg/kg bw all animals showed additional unspecific signs of nervous system impairment. The bodyweight gain of all animals was not affected. No mortality occurred at 300 mg/kg bw, but at 2000 mg/kg bw each 1/3 animals in step 3 and 4 died. Mortality was observed within 24 hours. No gross pathological findings were noted at necropsy in all surviving animals at 300 and 2000 mg/kg bw. In the 2 animals that died prematurely at 2000 mg/kg bw, gastrointestinal irritation was recorded beside unspecific signs of acute intoxication.

Conclusion

The acute oral toxicity (LD₅₀) of deoxyarbutin was >2000 mg/kg bw for female Sprague-Dawley rats.

Ref.: 4

Other non-validated acute oral toxicity studies in Sprague-Dawley rats estimated LD50 values of 5039 mg/kg bw (CI: 3807–6670 mg/kg bw) in males and 1260 mg/kg bw (CI: 918–1729 mg/kg bw) in females with deoxyarbutin (batch: HT0059.01) dissolved in propylene glycol/absolute ethanol/physiological saline (60:20:20%, v/v/v), while the respective estimated LD50 values for deoxyarbutin batch HT0059.04 dissolved in propylene glycol were reported as 3068 mg/kg bw (CI: 2270–4146) for males and 1148 mg/kg bw (CI: 843–1564) for females.

Ref.: 33, 34

3.3.1.2 Acute dermal toxicity

Guideline/method: OECD 402 (1987)
 Species/strain: Rat/Sprague-Dawley (CrI:CD(SD)IGS BR)
 Group size: 5 males and 5 females
 Test substance: deoxyarbutin
 Batch: 504007
 Purity: 99.5% (HPLC)
 Dose levels: 2000 mg/kg bw
 Route: dermal (semi-occlusive)
 Exposed area: 10% of body surface (52 cm²)
 Exposure: single application for 24 hours
 Observation period: 14 days
 GLP: Yes
 Date of report: August 2005

Rats were administered the neat test substance soaked with distilled water on a clipped area of the back (52 cm²) by means of a cellulose patch fixed with a non-irritating tape and covered semi-occlusively by a dressing. After a 24-h exposure period, the dressing was removed and residues were removed with a cellulose tissue moistened with water. The animals were observed for treatment-related effects within the periods 0-0.5, 0.5-1, 1-2, 2-4 and 4-6 hours after administration and then at least once a day for a total of 2 weeks. Observations included but were not limited to changes in skin, fur, eyes, the occurrence of secretions and excretions, autonomic activity, changes in gait, posture and the presence of convulsions. Bodyweights were determined prior to administration and on days 7 and 14 after application. Gross pathology was performed on all animals, which were sacrificed on day 14.

Results

No deaths, no signs of irritation nor any signs of systemic toxicity were observed clinically or by gross pathology. All animals gained bodyweight during the observation period.

Conclusion

The acute dermal toxicity (LD50) of deoxyarbutin was >2000 mg/kg bw for male and female Sprague-Dawley rats.

Ref.: 5

An acute dermal toxicity study was previously performed in male and female New Zealand White rabbits but has limited validity. The study was performed as a limit test; each group of 3 male and female animals received a 30% (w/v) solution of deoxyarbutin dissolved in propylene glycol at a dose level of 2000 mg/kg bw on about 10% body surface area and held in place by an occlusive dressing for 24h. No mortality occurred during the course of the 14-day observation period. Thus the estimated LD50 value for New Zealand White rabbits was >2000 mg/kg bw for both male and female animals.

Ref.: 35

3.3.1.3 Acute intraperitoneal toxicity

The acute intraperitoneal toxicity was investigated in male and female Sprague-Dawley rats. The rats received a single intraperitoneal injection of desoxyarbutin (batch: HT0059.01) dissolved in propylene glycol/absolute ethanol/physiological saline (60:20:20%, v/v/v) at dose levels of 240, 310, 400, 520, 680, and 1150 mg/kg bw. In addition, 3 male and 3 female rats received the vehicle at a dose volume of 5 ml/kg bw. Clinical signs of intoxication were recorded daily, the body weight was determined on day 7 prior to termination and all animals were subjected to gross pathology. All mortalities occurred by study day 5. This procedure resulted in an intraperitoneal LD50 value of 367 mg/kg bw in males (CI: 264–511 mg/kg bw) and 314 mg/kg bw in females (CI: 235–419 mg/kg bw).

Ref.: 36

Applicants overall conclusion on acute toxicity

The acute oral and dermal toxicity of desoxyarbutin can be regarded as low, with LD50 values for acute oral and dermal toxicity of >2000 mg/kg bw in rats.

3.3.2 Irritation and corrosivity

3.3.2.1 Skin irritation and corrosivity

In vitro

Guideline:	OECD 430 (2004)
Test system:	each 1 dorso-lateral skin disc of each 1 male Wistar rat
Group size:	3 males
Test substance:	desoxyarbutin
Batch:	501002
Purity:	99% (HPLC)
Dose level:	neat test substance
Route:	dermal (open)
Exposure:	single skin disc application for 24 hours at conditioned room temperature (22 ± 2 °C)
Negative control:	deionized water
Positive control:	36% HCl
Measurement:	transcutaneous electrical resistance (TER) prior to application and after test substance removal after 24 hours
Equipment:	AIM electronic databridge 6401 LCR, 100 Hz
GLP:	Yes
Date of report:	May 2005

The test substance was investigated for its possible corrosive potential by the transcutaneous electrical resistance (TER) test. Skin discs were obtained from the dorso-lateral region of 3 male Wistar rats. Prior to sacrifice, the hair of the animals was clipped on the back and flanks and washed on two days with an antibiotic solution. The animals were sacrificed, the skin was removed, stripped of excessive subcutaneous fat and the skin was placed on the end of polytetrafluoroethylene (PTFE) tube. The integrity of the skin discs was determined prior to application of the test substance by means of transcutaneous electrical resistance measurements. Thereafter a sufficient amount of the neat test substance was applied with a spatula on the skin discs obtained from each of the 3 rats to cover the whole epidermis surface. Deionized water was added and the tubes were shaken. After 24 hours contact time, the test substance was removed by washing with tap water. Immediately thereafter, the TER was measured. Deionized water and 35% HCl solution were used as negative or positive controls, respectively.

Results

The mean TER of deoxyarbutin treated skins was 16 kΩ and for deionized water was 14 kΩ, while the positive control, 36% HCl revealed a mean TER 0.7 kΩ. The TER values of the negative and positive controls corresponded clearly to the respective guideline requirements and demonstrated the suitability and sensitivity of the test system.

Conclusion

Under the experimental conditions reported, deoxyarbutin did not exhibit any corrosive potential to the skin *in vitro*, when tested neat in the TER test.

Ref.: 6

SCCS comment

Based on this test, no conclusion on skin irritation potential can be drawn.

In vivo

Guideline:	OECD 404 (2002)
Species/strain:	Rabbit/New Zealand White
Group size:	3 females
Test substance:	deoxyarbutin
Batch:	504007
Purity:	99.5% (HPLC)
Concentration:	0.5 g of unchanged test substance moistened with 1.0 ml deionized water
Route:	intact skin (semi-occlusive)
Exposure:	4 h
Observation period:	up to 72 h after patch removal
GLP:	Yes
Date of report:	August 2005

Deoxyarbutin was investigated for its acute dermal irritation potential in 3 female New Zealand White rabbits. The hair was clipped on the dorsal area of the trunk one day prior to application. An amount of 0.5 g of the test substance was moistened with 1.0 ml deionized water, applied to the test site (2.5 x 2.5 cm) and held in place using a non-irritating tape covered by a semi-occlusive dressing. The duration lasted 4 h and during that period, the animals were prevented from accessing the test area by being fitted with plastic collars. The animals were examined for erythema/eschar and oedema as well as for other local or systemic signs of toxicity after about 1, 24, 48 and 72 h after patch removal.

Results

There were no mortalities and no signs of systemic toxicity or irritation noted during the entire observation period. The mean scores for erythema/eschar and oedema were 0.0 for each animal at each observation time point.

Conclusion

Under the condition of this study, deoxyarbutin was shown to be non-irritating to the intact skin of New Zealand White rabbits.

Ref.: 7

Studies on the skin irritating potential of deoxyarbutin in humans are described in section 3.10.

3.3.2.2 Mucous membrane irritation / Eye irritation

Guideline:	OECD 405 (2002)
Species/strain:	Rabbit/New Zealand White
Group size:	3 females
Test substance:	desoxyarbutin
Batch:	504007
Purity:	99.5% (HPLC)
Concentration:	approximate equivalent of 0.1 ml of neat test substance (57 and 2x64 mg)
Route:	instillation in the conjunctival sac of the right eye
Observation period:	up to 72 h after instillation
GLP:	Yes
Date of report:	August 2005

The potential irritant effect of desoxyarbutin to the mucous membrane was investigated by instillation of an approximate equivalent to 0.1 ml of the neat test substance (i.e. 57, 64 and 64 mg) into the right conjunctival sac of each of three animals. The eyes were shortly held close to prevent a loss of the test substance. The left eyes remained untreated and served as controls. Both eyes of the animals were examined within 24 h before application and about 1, 24, 48, 72 h after application. The entire eye, with focus on cornea, iris and conjunctivae, was examined using an otoscope lamp.

Results

The treatment had no effect on the cornea or iris of the rabbits at any time-point. Exposure resulted in conjunctival redness of grade 1 during 1 h – 48 h in all three animals, resulting in a mean score of 0.7 in all animals for the period between 24 – 72 hours. Conjunctival chemosis of grade 2 was observed in all three animals after 1 hour of instillation; grade 2 was observed in one animal and grade 1 in two animals after 24 h; grade 1 was observed in one animal after 48 hours, while no effect was observed at 72 hours. The respective mean scores for conjunctival chemosis were 0.3; 0.3 and 1.0 (24 – 72 hours), respectively.

Conclusion

Desoxyarbutin was slightly and transiently irritating to the eyes of 3 New Zealand White rabbits. However, according to current EU classification requirements, a test substance is considered an eye irritant if the mean score for conjunctival redness and chemosis is equal to or greater than 2.5 and 2, respectively, in at least two rabbits. Since these threshold scores were not reached under the conditions of this study, the substance should not be considered to be an eye irritant according to EU classification criteria.

Ref.: 8

SCCS comment

It is noted that according to the CLP criteria, the classification cut-off value for redness and chemosis now is ≥ 2 . The SCCS agrees that classification of the test substance as an eye irritant is not warranted. However, as redness and particularly chemosis were observed during the observation period, the test substance is considered as a mild eye irritant.

There is another eye irritation study available using low volume and performed under GLP conditions. About 10 µl of 3% desoxyarbutin in a standard cream formulation was placed directly on the cornea of the right eye of each of 3 female New Zealand White rabbits. The other eye was left as untreated control. Animals were scored for signs of irritation at 24, 48, and 72 h post dosing using the Draize et al. (1959) scoring system. This low-volume eye irritation assay revealed no signs of eye irritation as the maximum average score was 0.0 at any time point.

Ref.: 37

SCCS comment

The low volume of test formulation (about 10 µl, i.e. 1/10 of the volume recommended in the OECD TG 405) used in this study precludes an evaluation of the eye irritating potential of the test formulation.

SCCS overall conclusion on irritation

Deoxyarbutin did not exhibit any corrosive potential to the skin in the *in vitro* TER test and was shown to be not irritating to the intact skin of New Zealand White rabbits.

In an eye irritation test with New Zealand White rabbits, the neat test substance was slightly and transiently irritating to the eyes. As redness and particularly chemosis were observed, the neat substance is considered as a mild eye irritant. Another test using standard cream formulation with 3% deoxyarbutin did not lead to signs of eye irritation in rabbits, but is not conclusive due to the very low volume of test formulation applied.

3.3.3 Skin sensitisation**Local Lymph Node Assays (LLNA) in mice**

Guideline:	OECD 429 (2002)
Species/strain:	Mouse/CBA/Ca
Group size:	4 female animals per group
Test substance:	deoxyarbutin
Batch:	504007
Purity:	99.5% (HPLC)
Concentrations:	10%, 25% and 50% in DMF
Solvent:	Dimethylformamide (DMF)
Route:	Epidermal (topical) application on the dorsal ear lobe surface
Application volume:	25 µl per ear of each animal
Application frequency:	single daily application for 3 consecutive days
Negative control:	DMF
Positive control:	25% (v/v) solution of hexyl cinnamic aldehyde (HCA) in acetone:olive oil (AOO, 4:1, v/v)
GLP:	Yes
Date of report:	December 2005

The sensitising potential of deoxyarbutin was tested in the murine local lymph node assay. Each group of four female mice was treated by topical application to the dorsal surface of each ear lobe (left and right) with the test substance dissolved in DMF at concentrations of 10%, 25% and 50%, DMF alone as vehicle control and 25% α -Hexylcinnamaldehyde (HCA) in acetone:olive oil (AOO) 4:1 as positive control. The application volume was 25 µl per ear. The preparations were made freshly each day prior to application and were spread over the entire dorsal surface of the ear once daily for three consecutive days. Five days after the first application, all mice were injected with 20 µCi of ^3H -thymidine in sterile saline. Five hours thereafter, all mice were sacrificed, the draining lymph nodes were excised, pooled and single cell suspensions of pooled lymph node cells were prepared. The cells were washed twice with phosphate buffered saline (PBS) and precipitated with 5% trichloroacetic acid (TCA) overnight at 4°C. The pellets were recovered by centrifugation and resuspended in 1 ml of TCA. The incorporation of ^3H -thymidine was measured by β -scintillation counting. The calculated stimulation indices (SI, test substance/negative control ratio) were decisive for the grading of the potential of sensitisation: The mice were observed daily for mortalities and clinical signs of intoxication on regular intervals. The application sites were observed for signs of irritation daily.

Results

The test substance did not lead to any overt sign of systemic toxicity or local irritation and there was no mortality. All mice appeared normal and bodyweight gain was not affected. The exposure to desoxyarbutin at 10, 5%, 25% and 50% resulted in stimulation indices of 1.8, 4.2 and 1.3, respectively.

The results can be summarised as follows:

Concentration	Substance	dpm	S.I.
100%	DMF	2057	1
10%(W/W)	Deoxyarbutin	3674	1.8
25%(W/W)	Deoxyarbutin	8714	4.2
50% (W/W)	Deoxyarbutin	2608	1.3
25% (V/V)	HCA in AOO	10770	19.8

DMF = negative (solvent) control, HCA = positive control, dpm = disintegration per minute, S.I = stimulation index

In the LLNA, a test material is considered to have skin sensitising activity if the stimulation index in any of the tested concentrations is equal to or greater than 3 to the concurrent vehicle control together with consideration of a dose-response. The positive control (25% HCA) led to a stimulation index (S.I.) of 19.8 confirming the sensitivity and suitability of the test system.

Conclusion

Based on these results, the authors of the study concluded that desoxyarbutin has to be regarded as a sensitiser. However, there was clearly no dose-response-relationship as the concentration of 10% resulted in a S.I. value of 1.8 and the highest tested concentration of 50% of a S.I. of 1.3, both values were clearly below the threshold value 3.0. Only the S.I. of the mid-concentration of 25% was above the threshold value. The applicant concluded that as desoxyarbutin did not reveal any clear sensitising potential at a concentration of 10%, it could be regarded as safe for the conditions of practical use. A possible low skin sensitising potential was noted at a concentration of 25% under the conditions of this murine local lymph node assay.

Ref.: 9

There is an additional local lymph node assay in mice with a slightly different study design, which was performed prior to the completion of the respective OECD 429 testing guideline.

Guideline/method:	not mentioned but with minor deviations comparable to OECD 429 (2002) (4 instead of 3 daily applications, 5 instead of 4 mice, exposure to ventral and dorsal ear lobe instead of dorsal, no positive control)
Species/strain:	Mouse/CBA/J
Group size:	5 female animals per group
Test substance:	desoxyarbutin
Batch:	PG21-69-1
Purity:	99.2%
Concentrations:	3%, 10% and 20% in acetone
Solvent:	Acetone
Route:	Epidermal (topical) application on the dorsal and ventral ear lobe surface
Application volume:	25 µl/animal (12.5 µl on ventral and dorsal ear lobe)
Application frequency:	single daily application for 4 consecutive days
Negative control:	a) untreated (naïve) mice b) Acetone
GLP:	Yes
Date of report:	June 1994

In this murine local lymph node assay, each group of five female mice was treated by topical application to the ventral and dorsal surface of each ear lobe (left and right) with the test substance dissolved in acetone at concentrations of 3%, 10% and 20% and acetone alone as carrier control. One group of 5 female mice remained untreated as the naïve control group. The application volume was 25 µl in total (12.5 µl on each ear side). The preparations were prepared fresh each day prior to application and were spread over the entire ear surfaces once daily for four consecutive days. Six days after the first application, all mice were injected with 20 µCi of ³H-thymidine in sterile saline. Five hours thereafter, all mice were sacrificed, the draining lymph nodes were excised and single cell suspensions were prepared. The incorporation of ³H-thymidine was measured by β-scintillation counting. The calculated stimulation indices (SI, test substance/naïve control ratio) were decisive for the grading of the potential of sensitisation: The mice were observed daily for mortalities, clinical signs of systemic intoxication or signs of irritation.

Results

The test substance did not lead to any overt sign of systemic toxicity or local irritation and there was no mortality. The exposure to deoxyarbutin at 3, 10% and 20% resulted in stimulation indices of 1.8, 1.5 and 2.0, respectively.

The results can be summarised as follows:

Concentration	Substance	dpm (mean)	S.I.
	Untreated control	100	1.0
100%	Acetone	93	0.93
3% (W/W)	Deoxyarbutin	177	1.77
10% (W/W)	Deoxyarbutin	153	1.53
20% (W/W)	Deoxyarbutin	201	2.01

dpm = disintegration per minute, S.I = stimulation index

Conclusion

It was demonstrated that under the conditions investigated, deoxyarbutin exhibited no potential to induce dermal sensitisation in this murine local lymph node assay when tested at concentrations up to 20% dissolved in acetone.

Ref.: 38

SCCS comment / overall conclusion on skin sensitization

The local lymph node assays performed indicate that deoxyarbutin is a moderate skin sensitiser according to the definitions provided in a SCCP memorandum (SCCP/0919/05).

3.3.4 Dermal / percutaneous absorption

Percutaneous absorption *in vitro*

Guideline:	OECD 428 (2004)
Test system:	Human skin
Test substance:	deoxyarbutin
Batch:	509014
Purity:	99.8% (HPLC)
Concentrations:	3% in a standard o/w emulsion
Skin preparation:	Dermatomed human skin from 3 female donors (approximately 400 – 500 µm thickness)
Replicates:	6 samples/donor
Positive control substance:	Caffeine (batch 066K0085), 10 mg/l in Krebs-Ringer-buffer (KBR) at pH 7.4
Skin temperature:	32 ± 2 °C
Test chamber:	Static glass diffusion cell (Franz type, 3.0 cm ²)
Route:	topical application

Exposure time:	24 h
Sampling time points:	0.5, 2, 4, 14, 19 and 24 hours
Tape stripping of <i>stratum corneum</i> :	20 tape strips (analysed individually or pooled per 6)
GLP:	Yes
Date of report:	December 2007

Deoxyarbutin was investigated for its permeation and penetration properties *in vitro* as a 3.0 % standard o/w emulsion on viable human skin. Initially, an analytical method for the determination of deoxyarbutin was implemented and validated. Within this process, the stability of the test item in the eluent and the test matrices (extraction + receptor medium) was tested for a period of 48 hours at 25°C ± 2°C and 4°C ± 2°C and additionally at 32°C ± 2°C for 48 hours for the permeation matrix. The content in the test formulation was determined by HPLC in triplicate. The study was performed under dynamic and non-occluded conditions using dermatomed human skin from 3 different female donors and 6 skin samples per donor. The skin thickness (approximately 400 - 500 µm) was measured immediately prior to each experiment and in total 6 samples were taken from the receptor medium at 0.5, 2, 4, 14, 19 and 24 hours. The test formulation was applied on each skin sample at an amount of 5 mg/cm², (~ 0.15 µg deoxyarbutin/cm²), left on the skin for 24 hours and then the residual amount was collected with cotton swabs. Thereafter, the concentration of deoxyarbutin in the skin was quantified. The *stratum corneum* was separated by tape stripping from the lower skin layers (dermis and epidermis), which were cryo-sectioned. The tape strips (20 strips total per sample) as sample for the *stratum corneum* were analysed as well as the cryosections as sample for the dermis/epidermis. Analysis was carried out by means of HPLC. A mass balance analysis was performed covering the initial and residual amounts in the formulation, in the *stratum corneum*, epidermis/dermis and acceptor compartment for the respective sampling time points. The sensitivity and suitability of the test system was investigated in parallel with caffeine at a concentration of 10 mg/l in Krebs-Ringer-buffer at pH 7.4 and respective results were compared with the historical control permeability coefficients.

Results

The HPLC method was successfully implemented and validated. The UV absorption at the wavelength of 223 nm was used for quantification of deoxyarbutin in the eluent mixture, the extraction medium and the acceptor medium. The LLOQ was 0.030 µg/ml in Krebs-Ringer bicarbonate buffer and eluent mixture. Deoxyarbutin was shown to be stable in the receptor medium during the course of the *in vitro* study. The recovery rate after incubation for 24 hours at 32°C was 103%.

The multiple endpoint analysis with caffeine revealed intact skin membranes demonstrating the suitability and sensitivity of the test system. After dermal application of a standard o/w emulsion containing 3% deoxyarbutin (about 160 µg deoxyarbutin/cm²) for 24 hours on the viable skin of three female donors, the mean amount of deoxyarbutin removed from the skin surface ranged from 43.28% to 62.58% of the dose applied in all experiments performed.

Deoxyarbutin was detected in all compartments relevant for assessment of dermal absorption and penetration, *e.g.* in the skin extracts and in the receptor solution samples; the chromatographic analyses revealed no indication for degradation. The mean recovery in the two first tape strips (upper *stratum corneum*) was 1.57% for all performed experiments. In the further 18 tape strips (lower *stratum corneum*), a mean recovery of 0.89 % was obtained.

The mean absorbed dose of deoxyarbutin representing the sum of the portions found in the viable epidermis, dermis and receptor medium, ranged from 42.11% to 70.85% in the three donor skin samples, with the greatest portion of deoxyarbutin in the receptor medium. The overall portion of the absorbed dose, dermally bioavailable, was 57.86%. The mean recovery of deoxyarbutin in the deeper skin layers of dermis and epidermis (cryocuts) represented only 0.26 % in total.

The total recovery rate for the three different skin donors ranged between 106.63% and 115.37% of the dose applied with an overall total recovery rate of 112.16% and was therefore in the acceptable range for a valid study. The details are provided in the following table:

Amount of desoxyarbutin	Expressed as $\mu\text{g}/\text{cm}^2$ of skin surface mean \pm S.D. (n = 18)	Expressed as % of dose mean \pm S.D. (n = 18)
Formulation applied	160.81 \pm 1.58	100
Receptor	93.24 \pm 20.05	57.86 \pm 11.90
Skin surface	82.90 \pm 12.18	51.58 \pm 8.11
2 Tape strips	2.52 \pm 1.97	1.57 \pm 1.23
18 Tape strips	1.43 \pm 0.12	0.89 \pm 0.07
Cryocuts (dermis/epidermis)	0.42 \pm 0.10	0.26 \pm 0.06
Dose absorbed (i.e. dermally bioavailable)	93.66 \pm 20.15	58.12 \pm 11.96
Total Recovery	180.51 \pm 34.42	112.16 \pm 3.93

Conclusion

After dermal application of 3% desoxyarbutin in a standard o/w emulsion (160.81 μg desoxyarbutin/ cm^2) applied for 24 hours to the viable skin of three human donors *in vitro*, desoxyarbutin was detected in all relevant compartments; the recovery showed no indication of degradation of the test compound. Under the conditions of this study, a high dermal availability of 58.12%, corresponding to 93.66 μg desoxyarbutin/ cm^2 , was observed.

Reference: 27

In an older exploratory screening study, the penetration of desoxyarbutin (no information on concentration and application area) was investigated *in vitro* using dermatomed skin from hairless albino guinea pigs. The dermatomed skin had a thickness of about 450 μm and was placed on a flow-through system consisting of a Manostat cassette pump, ISCO fraction collectors, a circulating temperature controlled water bath, and two banks each of 7 Teflon® flow-through diffusion cells. Prior to use, the integrity of each skin sample was determined grossly. The receptor fluid (modified HBSS; Hanks Balanced Salt Solution) was perfused beneath and in contact with the skin sample by means of a peristaltic pump, and was collected automatically (1.5 mL/h) at 1-hour intervals. The skin penetration samples were analysed by means of HPLC. Desoxyarbutin was shown to penetrate rapidly through the guinea pig skin *in vitro*. The steady state permeability constant was calculated as $K_p = 1.3 \times 10^{-4}$ cm/h, indicating that 100% of a 0.5 mg dose of a 1% desoxyarbutin cream would penetrate through guinea pig skin in 24 hours.

Ref.: 39

Percutaneous absorption *in vivo*

There is no validated scientific or regulatory *in vivo* skin penetration study in experimental animals available. However, an older exploratory screening study in pigmented Guinea pigs, which was primarily designed to investigate the metabolism of topically applied desoxyarbutin, indicated that desoxyarbutin may rapidly penetrate through the skin. The calculated effective permeability constant (K_{peff}) was 1.9×10^{-4} cm/h. (39). In a pilot study with topical application of radiolabelled 3% desoxyarbutin to guinea pigs, 90% of the radioactivity was detected in urine after 48h, 52-57% as the glucuronide and ~30% as the sulphonated conjugate, so that the desoxyarbutin was nearly quantitatively absorbed.

SCCS comment / conclusion on dermal/percutaneous absorption

The human *in vitro* percutaneous absorption study showed that after the dermal application of 3% desoxyarbutin in a standard o/w emulsion (160.81 μg desoxyarbutin/ cm^2) applied for

24 hours to the viable skin of three female donors, deoxyarbutin was detected in all compartments relevant for assessment of dermal absorption and penetration. There was no evidence for degradation of the parent compound. A high dermal availability of $58.12 \pm 11.96\%$, corresponding to $93.66 \pm 20.15 \mu\text{g deoxyarbutin}/\text{cm}^2$, was observed.

Because of some limitations in the *in vitro* study using human skin (low number of donors), the SCCS considers the mean+2 SD, i.e. 82.04% or $134 \mu\text{g}/\text{cm}^2$ for dermal penetration.

3.3.5 Repeated dose toxicity

3.3.5.1 Repeated Dose (28 days) oral / dermal toxicity

28-day oral toxicity study in rats

Guideline:	OECD 407 (1995)
Species/strain:	Rat/F344
Group size:	Main group: 5 males and 5 females per group
Satellite group:	5 males and 5 females (control and high dose groups)
Test substance:	deoxyarbutin
Batch:	504007
Purity:	99.5% (HPLC)
Dose levels:	0, 100, 316, 1000 mg/kg bw
Dose volume:	5 ml/kg bw
Vehicle:	Corn oil
Route:	Oral (gavage)
Exposure period:	28 days
Exposure frequency:	daily
Recovery period:	14 days for control and high dose groups
GLP:	Yes
Date of report:	January 2006

The subacute toxicity of deoxyarbutin was examined in a 28-day oral toxicity study in male and female F344 rats. Each of the 5 males and 5 females per group received the test substance as an oily solution (corn oil) at dose levels of 0, 100, 316 and 1000 mg/kg bw daily by gavage for 28 days (main group). The volume administered was 5 ml/kg bw. In addition, two groups of 5 males and 5 females each, i.e. one high dose satellite group and one control satellite group, were treated in the same manner as their corresponding groups, but were kept for a further 14 days without test substance administration to observe the reversibility or persistence of test substance-induced findings. The dose selection was based on a previous range-finding study with daily administration of oily solutions at dose levels of 0, 32, 100, 320 and 1000 mg/kg bw for 7 consecutive days. The test substance solutions were analysed for correct concentrations, homogeneity and stability over 4 hours.

The animals were observed for clinical signs and mortality at regular intervals including a detailed clinical observation once a week. A functional observation including measurements of motor activity and sensory reactivity was performed at the end of the administration period in all treated main group animals and towards the end of the recovery period. Bodyweights and food consumption were recorded weekly. Blood samples for haematological and clinical chemistry were taken at day 29 in all main group animals and at day 43 in the respective satellite animals. At termination of treatment and after recovery had elapsed, all animals were sacrificed and macroscopically examined, organs were weighed and histopathology was performed.

Results

The analysis confirmed the stability of the oily solutions for at least 4 hours at room temperature and the correctness of the concentrations. The homogeneity was also confirmed with the exception that the one high dose sample was slightly outside the

acceptable range. However, as the concentration was slightly higher, the validity of the study was not impaired.

Range-finding study: There was no mortality and only the animals of the 320 and 1000 mg/kg bw groups suffered transiently from unspecific signs of impaired health status. At 1000 mg/kg bw, the bodyweights and food consumption of the animals of both groups were slightly but not statistically significantly affected. At necropsy, no substance-related finding was noted in any animal. Therefore, 1000 mg/kg bw was selected as the highest dose level for the subsequent 28-day main study.

28-day main study:

There was no substance-related mortality but one high dose female of the main group died on day 2 due to a gavage error and was replaced with an animal from the recovery group. Substance-related findings occurred only in the animals of the 1000 mg/kg bw group and consisted of a transient occurrence of clinical findings, slightly reduced food consumption and retarded bodyweight gain during certain periods, minor haematological effects in females and slight impairment of single clinical chemistry parameters (increases of albumin and protein in males, reduced aspartate aminotransferase in females). At this dose level the relative liver weights of both sexes and the relative kidney weights in the males showed treatment-related increases. Slight deviations in the relative weights of the spleen, thymus and brain were observed and considered as secondary changes due to the impaired bodyweight gains at this dose level. There were no substance-related finding in histopathology and thus, no morphological correlates for the observed findings in clinical chemistry or the organ weight changes. In the low- and mid-dose animals, no biologically relevant findings were observed. The functional observation battery in the form of a detailed assessment of behaviour, motor activity, sensory reactivity, reflexes and grip strength revealed no indication of any neurological impairment at any dose level in any of the treated animals.

Conclusion

Deoxyarbutin was tolerated without mortality up to the high dose level of 1000 mg/kg bw. Slight signs of systemic toxicity occurred only at 1000 mg/kg bw in male and female rats but no specific mode of action or target organ was identified. There were no gross or histopathological findings and no impairment of any parameter in the comprehensive functional observation battery. Thus, the study authors stated that the no observed adverse effect level (NOAEL) was 316 mg/kg bw for male and female F344 rats under the conditions of this study.

Ref: 18

28 day dermal toxicity study in the rabbit

Guideline/method:	/
Species/strain:	Rabbit/New Zealand White
Group size:	5 males and 5 females per group
Test substance:	deoxyarbutin
Batch:	HT0059.01-04
Purity:	99%
Dose levels:	3% deoxyarbutin in a cream formulation
Control:	Vehicle cream formulation
Dose volume:	2 ml/kg bw
Route:	Dermal (open, intact skin)
Exposure period:	28 days
Exposure frequency:	once daily for 6 h, 7days/week
GLP:	Yes
Date of report:	October 1994

The subacute dermal toxicity and cumulative irritation of deoxyarbutin were examined in a 28-day dermal toxicity screening study in male and female New Zealand White rabbits. Each animal, 5 males and 5 females per group, was administered a cream formulation with 3%

deoxyarbutin once a day for 6 hours, 7 days per week for 28 days. The application volume was 2 ml/kg bw and the covered area corresponded to about 15% of the body surface. The application area remained open but a collar was placed on each animal to prevent ingestion. The control animals of the same size received the cream formulation. After 6 hours of exposure, the skin was washed with propylene glycol, followed by a tepid water wash before drying. The animals were observed continuously for signs of toxicity. Bodyweight was recorded once a week. The skin at the application area was investigated before the daily exposure. Blood samples for haematology and clinical chemistry were taken in weeks 2 and 4 and urine samples in week 4. At termination, the animals were sacrificed and examined for gross pathological findings, organs were weighed and histopathology was performed.

Results

No animal died prematurely. The dermal application of 3% deoxyarbutin in a cream formulation led to a transient retardation of the bodyweight gain in males and dermal irritation in males and females characterised by moderate to marked erythema. Macroscopic findings in the form of thickening with red discoloration and microscopic lesions consisting of inflammation of the dermis and hyperkeratosis and acanthosis of the epidermis were limited to the treated skin. However, the incidences of all of these findings were higher with the vehicle cream formulation. With the exception of the skin findings, there were no further treatment-related clinical observations or findings in haematology, clinical chemistry, urinalysis or pathology.

Conclusion

Since the macroscopically and histopathologically observed dermal irritation was more pronounced in the vehicle control group, no final conclusion on the cumulative irritation potential of 3% deoxyarbutin can be drawn. In any case, the repeated application for 28 consecutive days led to no systemic toxicity in male and female rabbits under the condition of the study. However, based on the limitations, this study can only be considered as an exploratory screening study.

Reference: 40

3.3.5.2 Sub-chronic (90 days) dermal toxicity

Guideline/method:	/
Species/strain:	Rabbit/New Zealand White
Group size:	5 males and 5 females per group
Test substance:	deoxyarbutin
Batch:	HT0059.02
Purity:	99%
Dose levels:	1, 5, 40% deoxyarbutin dissolved in propylene glycol/ethanol (75%/25%, V/V)
Control:	propylene glycol/ethanol (75%/25%, v/v) vehicle
Dose volume:	2 ml/kg bw
Route:	Dermal (open, intact skin)
Exposure period:	91 days
Exposure frequency:	once daily for 6 h, 7days/week
GLP:	Yes
Date of report:	October 1994

The subchronic toxicity of the test substance was examined in a 91-day dermal toxicity study in male and female New Zealand White rabbits. Each animal (5 males and 5 females per group), was administered 1, 5 and 40% deoxyarbutin dissolved in the vehicle once a day for 6 hours, 7 days per week for 91 days. The application volume was 2 ml/kg bw and the covered area corresponded to about 15% of the body surface. The application area remained open but a collar was placed on each animal to prevent ingestion. The control animals (same group size) received the vehicle (propylene glycol/ethanol (75%/25%, v/v)). After 6 hours of exposure, the skin was washed with propylene glycol, followed by tepid

water wash before drying. The animals were observed continuously for signs of toxicity. Bodyweight was recorded once a week. The skin at the application area was investigated before the daily exposure. Blood samples for haematology and clinical chemistry were taken in weeks 2 and 4 and at termination, and urine samples were taken at termination. After 91 days of treatment had elapsed, the animals were sacrificed and examined for gross pathological findings; organs were weighed and histopathology was performed.

Results

No animal died prematurely. The dermal application of 1, 5 and 40% deoxyarbutin in the propylene glycol/ethanol vehicle led to no adverse clinical signs and no effects on bodyweight gain. Slight erythema was noted in all groups. Moderate erythema was noted only in the high-dose group. The gross lesions were limited to the treated skin area of the high-dose animals and consisted of scaling and red discoloration. Histopathology revealed lesions in form of chronic inflammation of the dermis and hyperkeratosis and acanthosis of the epidermis in the vehicle control as well as in the test-substance treated animals. There were no treatment-related findings in haematology, clinical chemistry or urinalysis. Pathology revealed no macroscopic or microscopic treatment-related finding other than the skin effects and there were no substance-induced effects on any organ weight.

Conclusion

The results indicated that subchronic dermal treatment of deoxyarbutin at concentrations of 1, 5 or 40% in propylene glycol/ethanol vehicle was tolerated without mortality or adverse clinical findings or an effect on bodyweight gain. Dermal irritation scoring showed that both the vehicle and the test substance produced dermal irritation, slightly more pronounced at the high concentration. Histopathology revealed chronic skin lesions in all groups including the vehicle control; there were only slight differences in severity but not in the incidence, suggesting that the vehicle was also responsible for the chronic inflammatory skin effect. Therefore, no final conclusion on the chronic cumulative irritation potential of deoxyarbutin can be drawn. However, no signs of systemic toxicity were noted up to the highest concentration of 40% deoxyarbutin in propylene glycol/ethanol (corresponding to about 800 mg/kg bw) in male and female rabbits under the condition of the study.

Ref.: 40

3.3.5.3 Chronic (> 12 months) toxicity

No chronic toxicity study with deoxyarbutin is available.

SCCS overall conclusion on repeated dose toxicity

The systemic toxicity after repeated **oral** application for 28 days to male and female rats was low and effects could only be observed at the currently accepted limit dose level of 1000 mg/kg bw for repeated toxicity studies. They consisted of transient clinical findings, slightly reduced food consumption and retarded body weight gain, minor haematological effects in females and slight impairment of single clinical chemistry parameters. In addition, the relative liver weights of both sexes and the relative kidney weights of the males were increased, but without any histopathological correlates. The functional observation battery revealed no indication of any neurological impairment at any dose level. Clear or severe organ toxicity was not observed morphologically even at the limit dose of 1000 mg/kg bw. Oral dosing may be considered as worst-case scenario for deoxyarbutin since it is likely that the acidic stomach environment led to the formation of a (non-quantifiable) portion of hydroquinone, causing the observed effects.

The **No-Adverse-Effect-Level (NOAEL) for subacute toxicity after 28-day oral treatment was 316 mg/kg bw** in male and female rats. This value may be considered as the worst-case scenario for deoxyarbutin since the acidic stomach environment will lead to its degradation to hydroquinone which then causes the observed toxicity.

Repeated **dermal** application of deoxyarbutin to rabbits either as 3% cream formulation for 28 days or as 1, 5 and 40% in propylene glycol/ethanol solution for 91 days did not lead to any substance-related systemic findings up to the highest dose level investigated. The cumulative dermal irritation potential of deoxyarbutin cannot be assessed from these studies as the vehicle cream formulation led to more pronounced findings than the cream with 3% deoxyarbutin, and the propylene glycol/ethanol vehicle used in the 91-day study was *per se* irritating and led to chronic dermal inflammation. For subchronic dermal treatment; the highest dose of 40% deoxyarbutin in propylene glycol/ethanol vehicle, corresponding to about **800 mg/kg bw, was the No-Adverse-Effect-Level (NOAEL) for systemic toxicity in male and female rabbits**. This value will be used for risk assessment and the calculation of the margin of safety (MoS).

3.3.6 Mutagenicity / Genotoxicity

3.3.6.1 Mutagenicity / Genotoxicity *in vitro*

Bacterial reverse mutation assay

Guideline/method:	Comparable to OECD 471
Test system:	<i>Salmonella typhimurium</i> strains TA98, TA100, TA1535, TA1537, TA1538 and <i>Escherichia coli</i> strain WP2 <i>uvrA</i> and WP2
Replicates:	triplicate plates
Test substance:	deoxyarbutin
Batch:	HT0059.01
Purity:	99.2%
Concentrations:	0, 33, 100, 333, 1000, 3333, 5000 µg/plate without and with S9-mix
Solvent:	Acetone
Treatment:	direct plate incorporation method
Positive Controls:	without S9-mix: 2-nitrofluorene, sodium azide, 9-amino-acridine, methyl methanesulfonate with S9-mix: 2-aminoanthracene,
GLP:	in compliance
Date of report:	March 1994

Deoxyarbutin was tested for mutagenicity in the reverse mutation assay on bacteria with and without metabolic activation. The S9 fraction was prepared from Aroclor 1254 induced male Sprague-Dawley rat liver. The plate incorporation method was used. The *S. typhimurium* strains TA98, TA100, TA1535, TA1537, TA1538 and *E. coli* strain WP2 *uvrA* and WP2 were exposed to the test substance (dissolved in acetone) at concentrations ranging from 33 – 5000 µg/plate. For control purposes, the solvent and positive controls were also investigated.

Results

Precipitation was not observed with any *S. typhimurium* or *E. coli* strain up to the highest concentration tested. No bacteriotoxicity was noted in any strain with the exception of *E. coli* strain WP2 at high concentrations of ≥ 3333 µg/plate. The test substance did not induce a biologically relevant increase in revertant colony numbers in the bacterial strains at any concentration tested in the presence or absence of metabolic activation. The sensitivity and validity of the test system used was demonstrated by the expected induction of a significantly increased number of revertants with the positive controls.

Conclusion

Under the experimental conditions used, deoxyarbutin was not mutagenic in this gene mutation test in bacteria.

Ref.: 41

Chromosome aberration test in cultured human lymphocytes

Guideline:	OECD 473 (1997)
Test system:	Human lymphocytes
Replicates:	duplicate culture in two experiments
Test substance:	desoxyarbutin
Batch:	504007
Purity:	99.5% (HPLC)
Concentrations:	72, 216, 647, 1940 µg/ml without S9-mix, 3 h treatment 24, 72, 217, 650 µg/ml with S9-mix, 3 h treatment 72, 217, 647, 650, 1940 without S9-mix, 20 h treatment
Treatment:	3 h treatment without and with S9-mix; harvest time 20 h after the start of treatment 20 h treatment without S9-mix; harvest time immediately after the end of treatment
Solvent:	DMSO
Positive Controls:	without S9-mix: Methane sulfonic acid methylester; with S9-mix: cyclophosphamide
GLP:	in compliance
Date of report:	January 2006

Desoxyarbutin was tested for its potential to induce structural chromosome aberrations in human lymphocyte cultures prepared from the blood of three female and one male donor in two independent experiments. The test substance was tested in the presence and absence of metabolic activation. The S9 fraction was prepared from Aroclor 1254 induced Sprague-Dawley rat liver. The test article was dissolved in DMSO. After sampling of the primary lymphocytes, the cultures were incubated for 48 hours in the presence of phytohaemagglutinin. The cells were exposed to the test substance for 3 or 20 hours in the absence of metabolic activation and for 3 hours in the presence of S9-mix. Colcemid was added to the cultures 2 hours prior to harvest. The lymphocytes were processed, fixed and then treated with Giemsa stain. The mitotic indices were calculated from 2000 lymphocytes per culture to evaluate cytotoxicity. Methane sulfonic acid methylester for the non-activation set and cyclophosphamide requiring activation served as positive control substances. A solvent control (DMSO) was also included in the test.

Results

Cytotoxicity was observed in cultures in the presence or absence of metabolic activation. Without S9-mix and after 3 hours of incubation, no mitoses were found at 1940 µg/ml. The three remaining concentrations were evaluated and cytotoxicity complied with the requirements of the OECD TG.. After 20 hours without S9-mix, only the mitotic index of the lowest concentration complies with the OECD TG. Consequently, only this concentration gave reliable results. Treatment of culture for 3 hours in the presence of S9-mix resulted in no mitoses at 1940 µg/ml. Three other concentrations were evaluated and had cytotoxicity levels in agreement with the OECD TG.

A biologically relevant increase in the number of cells with chromosomal aberrations was not observed after the treatment for 3 hours without metabolic activation at any concentration. The same exposure period (3 h) with metabolic activation led to an increase in cells with structural aberrations at 650 µg/ml.

The prolonged treatment of 20 hours without S9-mix caused an increase in cells with structural aberrations at 24 µg/ml.

The sensitivity of the test system was shown since the vehicle control led to no findings but the positive control substances showed statistically expected increases in the number of cells with chromosomal aberrations.

Conclusion

Under the experimental conditions used, desoxyarbutin was genotoxic (clastogenic and/or aneugenic) in this *in vitro* chromosome aberration test with human lymphocytes.

Ref.: 19

3.3.6.2 Mutagenicity / Genotoxicity <i>in vivo</i>
--

Mouse Micronucleus Assay with intraperitoneal application

Guideline:	OECD 474 (1997)
Species/strain:	Mouse/ICR
Group size:	5 male and 5 female mice per dose group/sacrifice time
Test substance:	desoxyarbutin
Batch:	509014
Purity:	99.8% (HPLC)
Dose levels:	0, 62.5, 125 or 250 mg/kg bw
Exposure:	Single application
Route:	Intraperitoneal (i.p.)
Vehicle:	1% Methylcellulose (MC) in phosphate buffered saline
Sacrifice Times:	24 hours and 48 hours (vehicle and high dose only) after start of treatment
Negative control:	vehicle
Positive control:	Cyclophosphamide (CP)
GLP:	in compliance
Date of report:	January 2007

The ability of desoxyarbutin to cause chromosomal damage *in vivo* was investigated in the mouse bone marrow micronucleus test. In the range-finding study, 3 male and 3 female ICR mice were intraperitoneally (i.p.) injected with the test substance at 200, 250, 500, 1000 or 2000 mg/kg bw to determine the maximum tolerated dose to be used in the definitive micronucleus study. All mice were weighed immediately prior to dose administration and were observed immediately after test substance administration and daily thereafter for 3 days for clinical signs of toxicity. Bodyweights were recorded before dose administration on days 0 and 3.

In the micronucleus test, 5 male and 5 female mice per dose group received a single i.p. injection of the test substance at 62.5 and 125 mg/kg bw, while 15 animals of both sexes (including 5 replacement animals per sex) received 250 mg/kg bw. All animals were observed for clinical signs of intoxication at regular intervals throughout the study period and the bodyweights were determined prior to application. In addition, urine samples were collected at 2, 8 and 24 hours after treatment and blood samples were taken at 24 and 48 hours after treatment, but were not further analysed.

Toxicity and thus exposure of the target cells was determined by measuring the ratio between polychromatic and total erythrocytes (PCE/NCE). The results obtained for the negative and positive controls were compared to historical control data for validation purposes.

Results

The test substance formed a cloudy white suspension at 100 mg/ml.

In the range-finding study, mortality was observed in all males and all females at 1000 and 2000 mg/kg bw. Lethargy was observed in all males and all females at 200 and 300 mg/kg bw and all males and 1 of 3 females at 500 mg/kg bw. In addition, irregular breathing and deep and prolonged prostration were recorded for all animals of both sexes at 500 mg/kg bw. Based on mortality and clinical signs, doses of 62.5, 125 and 250 were selected for the micronucleus test.

In the micronucleus test, no mortality was observed. Clinical findings were observed and consisted of piloerection in all males and all females at 125 and 250 mg/kg bw and lethargy

in all males and all females at 250 mg/kg bw. Prostration occurred immediately after dosing (for approximately 10-15 minutes post-dose) in 2 of 5 males and 1 of 5 females at 125 mg/kg bw and all males and all females at 250 mg/kg bw. All mice treated with the vehicle or the test article at 62.5 mg/kg bw appeared normal following dose administration and during the course of the study.

No biological relevant and statistically significant increase in the number of micronucleated polychromatic erythrocytes in any of the test substance treated groups relative to the respective vehicle control groups was observed at 24 or 48 hours after dose administration. Exposure of the bone marrow was indicated as reductions in the PCE/NEC ratio of 24% and 18% were observed at 250 mg/kg in the 24 hour male and female groups relative to the respective vehicle controls. In addition, reductions of 11% and 17% in the 48-hour male and female groups at 250 mg/kg were also observed. In the vehicle group, the incidence of micronucleated PCEs did not exceed the historical control group ranges, while the positive control induced a significant increase in its incidence indicating the suitability and sensitivity of the test system.

Conclusion

Under the experimental conditions used, desoxyarbutin is not genotoxic (clastogenic and/or aneugenic) in this micronucleus test in mice.

Ref.: 23

Mouse Micronucleus Assay with oral application

Guideline/Method:	OECD 474 (1997)
Species/strain:	Mouse/NMRI
Group size:	5 male and 5 female mice per dose group/sacrifice time
Test substance:	desoxyarbutin
Batch:	509014
Purity:	99.7% (HPLC)
Dose levels:	0, 300, 600 and 900 mg/kg bw
Exposure:	Single application
Route:	Oral (gavage)
Vehicle:	Corn oil
Sacrifice Times:	24 hours and 48 hours (vehicle and high dose only) after start of treatment
Negative control:	vehicle
Positive control:	Cyclophosphamide
GLP:	in compliance
Date of report:	February 2006

Desoxyarbutin was examined for the potential to induce chromosomal damage *in vivo* in the mouse bone marrow micronucleus test using the oral route of application. A range-finding study to determine the maximum tolerated dose level was performed in 1 male and 1 female NMRI mouse treated with dose levels of 500, 1000 or 1500 mg/kg bw. The mice were observed for mortality and clinical signs of toxicity until termination at 48 hours after application.

In the micronucleus test, 5 male and 5 female mice per dose group received a single oral administration of desoxyarbutin suspended in corn oil at 300 and 600 mg/kg bw, while 12 males and 15 females (including 2 male and 5 female replacement animals) received 900 mg/kg bw. All animals were observed for clinical signs of intoxication at regular intervals throughout the study period.

Mice were euthanised at 24 h and at 48 hours (high dose and vehicle control). Toxicity and thus exposure of the target cells was determined by measuring the ratio between polychromatic and total erythrocytes (PCE/NCE). The results obtained for the negative and positive controls were compared to historical control data for validation purposes. A statistical analysis of the results was performed.

Results

In the range-finding study, one male mouse died at 1000 and one female at 1500 mg/kg bw associated with severe clinical findings prior to death and in the concurrent surviving animal at 1500 mg/kg bw. At 500 mg/kg bw, the female showed decreased motor activity but no clinical findings were noted in the male animal. Both mice survived until termination. Based on mortality and clinical signs, doses of 300, 600 and 900 were selected for the micronucleus test.

In the micronucleus test, mortality was observed in 1 male and 5 females at 900 mg/kg bw. The death occurred between about 3 and 24 hours after administration of the test substance. The deceased animals were replaced by identically treated and dosed animals. All other animals survived until the scheduled sacrifice. Dose-dependently pronounced clinical findings were observed at 600 and 900 mg/kg bw consisting of decreased motor activities up to disturbed locomotion, tremours, unconsciousness and white-appearing eyeballs. No clinical signs of toxicity were noted in the low dose group animals.

Bone marrow cytotoxicity substantiated by markedly or statistically significantly lowered percentages of nucleated cells as well the percentages of polychromatic erythrocytes was noted at all tested dose levels 24 hours after the administration in the females and at the mid- and high-dose level in males as well as at the high-dose level at the 48-hour harvest time point in both sexes. The females appeared to be more susceptible than the males.

An increased number of polychromatic erythrocytes with micronuclei was observed in males and in females. While in females this effect was statistically significant and occurred at all dose levels and both time points, the effect in males achieved no statistical significance and was only observed at 600 and 900 mg/kg bw. In the vehicle group, the incidence of micronucleated PCEs did not exceed the historical control group ranges, while the positive control induced a significant increase in its incidence indicating the suitability and sensitivity of the test system.

Conclusion

Under the experimental conditions used, desoxyarbutin is genotoxic (clastogenic and/or aneugenic) in this micronucleus test with oral application in mice.

Ref.: 20

This result is in line with another oral micronucleus test in mice using a different batch of desoxyarbutin (batch 504007) and performed in parallel.

Ref.: 21

SCCS comment

A positive result in the micronucleus test with oral administration can be expected. The oral route is inappropriate when the substance is intended for dermal use since desoxyarbutin is hydrolysed at low pH values. In mice, the stomach pH is generally between 1 – 2, so that an immediate and complete breakdown of desoxyarbutin to hydroquinone and other compounds will occur. Thus, with oral application, not desoxyarbutin *per se* will be investigated but hydroquinone, a compound which is known to be clastogenic, both *in vitro* and *in vivo* (References: 3, 31). This has to be taken into consideration when discussing the value of the results of this mouse micronucleus test using the oral route of application. Consequently, SCCS considers the result of this oral micronucleus test not relevant to determine the genotoxicity of desoxyarbutin in the context of dermal application.

Mammalian Spermatogonial Chromosome Aberration Test

Guideline/Method:	OECD 483 (1998)
Species/strain:	Mouse/ICR
Group size:	5 male rats per dose group/sacrifice time
Test substance:	desoxyarbutin
Batch:	509014

Opinion on desoxyarbutin - Tetrahydropyranyloxy Phenol

Purity:	99.8% (HPLC)
Dose levels:	0, 62.5, 125 or 250 mg/kg bw
Exposure:	Single application
Route:	Intraperitoneal (i.p.)
Vehicle:	1% Methylcellulose (MC) in phosphate buffered saline
Sacrifice Times:	24 hours and 48 hours (vehicle and high dose only) after start of treatment
Negative control:	vehicle
Positive control:	Mitomycin C
GLP:	In compliance
Date of report:	October 2007

The chromosome-damaging potential of deoxyarbutin was investigated in a murine spermatogonial chromosome aberration test in ICR mice. Each of 5 male mice per dose group received a single i.p. injection of the test substance at 62.5 and 125 mg/kg bw, while 15 animals (including 5 replacement animals) received 250 mg/kg bw. Mice were euthanised 24 hours and 48 hours (high dose test substance group and vehicle control) after the single i.p. injection. The testes were removed from each mouse, and spermatogonial cells were isolated from the tubules, smeared onto the microscope slide and stained with Giemsa stain. One hundred metaphase cells (metaphase spreads) per mouse were examined by light microscopy and scored for chromatid-type and chromosome-type aberrations (structural aberrations). In addition, the mitotic index was recorded as the percentage of cells in mitosis based upon 1000 cells counted per mouse.

Results

No mortality occurred. Piloerection was observed in all mice at 125 and 250 mg/kg bw and lethargy and prostration were recorded in all mice at 250 mg/kg bw. No clinical findings were noted at 62.5 mg/kg bw or in any of the control groups.

There was no biologically relevant and statistically significant increase in the number of cells with structural chromosome aberrations relative to the respective vehicle control groups. There were no reductions in the mitotic indices at 24 or 48 hours after dose administration in the test substance treatment groups relative to the respective vehicle control groups, indicating that deoxyarbutin was not toxic to the spermatogonial cells. In the vehicle group the incidence of structural chromosome aberrations did not exceed the historical control group ranges, while the positive control induced a significant increase in its incidence indicating the suitability and sensitivity of the test system.

Conclusion

Under the experimental conditions used deoxyarbutin is not considered genotoxic (clastogenic and/or aneugenic) in this test.

Ref.: 25

SCCS comment

The lack of toxicity of deoxyarbutin may indicate that the spermatogonial cells were not exposed. SCCS considers this test of limited value.

Overall SCCS conclusion on mutagenicity

Overall, the genotoxicity of deoxyarbutin is sufficiently investigated in valid genotoxicity tests for the 3 endpoints of genotoxicity: gene mutations, chromosome aberrations and aneuploidy.

Deoxyarbutin did not induce gene mutations in bacteria. In human lymphocytes, deoxyarbutin showed a clastogenic potential with and without metabolic activation. However, as the clastogenic reactions were observed with and without metabolic activating enzymes, and deoxyarbutin is known to be unstable at lower pH values, chemical hydrolysis to hydroquinone can have occurred to a certain extent. Then, instead of deoxyarbutin, its chemical breakdown product hydroquinone, a known clastogenic and cytotoxic agent *in vitro* and *in vivo*, may have been the causative agent.

The positive *in vitro* results on clastogenicity were not confirmed in a micronucleus test with deoxyarbutin under the standard application procedure of intraperitoneal injection. In contrast, orally applied dose levels of deoxyarbutin induced micronuclei in the polychromatic erythrocytes of the bone marrow of male and female mice. This was expected due to the chemical breakdown of deoxyarbutin to hydroquinone in the acidic stomach environment. Thus, the oral application route to investigate the possible genotoxic or clastogenic potential of deoxyarbutin should be considered as inappropriate in the context of safety evaluation of the dermally applied substance. Deoxyarbutin did not induce an increase in the number of spermatogonial cells with structural or numerical chromosome aberrations. However, due to lacking indications of exposure of the spermatogonial cells, this test has limited value.

Based on the present reports, the parent compound deoxyarbutin can be considered to have no *in vivo* genotoxic potential and additional tests are unnecessary.

Arbutins are considered to be metabolised differently by different glycosidases or by spontaneous hydrolysis, yet they all form hydroquinone (HQ). The latter is considered as the genotoxic moiety; therefore a read-across based on HQ release is a possibility to assess the genotoxic potential of the arbutins as a group.

3.3.7 Carcinogenicity

No carcinogenicity study with deoxyarbutin is submitted.

3.3.8 Reproductive toxicity

No reproduction toxicity study with deoxyarbutin is submitted.

The repeated oral application of deoxyarbutin for 28 days up to the limit dose level of 1000 mg/kg bw in rats and the repeated dermal application for up to 3 months at the highest tested concentration of 40% (corresponding to about 800 mg/kg bw) led to no indication of any impairment of male or female reproductive organs.

Ref.: 18, 40

SCCS comment

Developmental and reproductive toxicity studies were not submitted.

3.3.9 Toxicokinetics and metabolism

In vitro metabolism

Guideline/method:	/
Test system:	Cryopreserved hepatocytes from female rabbits, rats, guinea pigs and human
Test substance:	deoxyarbutin
Batch:	509014
Purity:	99.8% (HPLC)
Concentrations:	5, 10 and 100 µM
Solvent:	Acetonitrile:5mM sodium hydroxide (1:1, V/V)
Positive Controls:	7-Ethoxycoumarin (7-EC)
Analysis:	Reverse phase HPLC with MS/MS detection
GLP:	No
Date of report:	October 2007

Deoxyarbutin was investigated for its hepatic metabolism *in vitro* in female cryopreserved rabbit, rat, guinea pig and human hepatocytes to gain information on the relative quantities

of the metabolites and their rates of production. The test substance was dissolved and diluted with acetonitrile: 5 mM sodium hydroxide (1:1, v/v) and was used at concentrations of 5, 10 and 100 µM. Prior to use, the hepatocytes were thawed and the viability checked then incubated with test substance concentrations of 5, 10 and 100 µM. 7-Ethoxycoumarin was included as positive control. The hepatocytes were exposed for 0, 60, 120 and 240 min and the reaction was terminated by addition of acetonitrile. Thereafter, the exposed hepatocyte mixtures were centrifuged, frozen and stored at -70 °C until analysis (LC-MS/MS and LC-MS). All samples were analysed for the occurrence and amount of desoxyarbutin, desoxyarbutin-glucuronide, desoxyarbutin sulphate, 7-ethoxycoumarin, 7-hydroxycoumarin, 7-hydroxycoumarin-glucuronide, 7-hydroxycoumarin sulphate, hydroquinone and 5-hydroxypentanal.

Results

The metabolism of desoxyarbutin was very similar in the hepatocytes of all the species examined. The levels of desoxyarbutin declined quickly from the hepatocyte preparations. Glucuronide and sulphate conjugation were the major routes of metabolism in all species studied. The major metabolite was desoxyarbutin-glucuronide. Peak areas of this conjugate were larger than the peak areas for the sulphate conjugate in all of the species examined, except for the guinea-pig hepatocyte incubations, where the two conjugates were detected at comparable levels. The metabolic activity of the guinea pigs' hepatocytes was slightly higher and those of the human hepatocytes slightly lower compared to the other species. – In none of the hepatocyte preparation of any species were hydroquinone, 5-hydroxypentanal (breakdown product of hydroquinone) or the glucuronide or sulphate conjugates of hydroquinone were detected at any time point. The sensitivity and suitability of the test system was demonstrated as the positive control substance 7-ethoxycoumarin was metabolized to its major metabolites, 7-hydroxycoumarin glucuronide and 7-hydroxycoumarin sulphate.

Conclusion

The hepatic metabolism of desoxyarbutin *in vitro* was examined in hepatocytes from rabbits, rats, guinea pigs and human and shown to be fast and complete. Glucuronidation and sulphation were demonstrated as the major metabolic pathways. Virtually no metabolism to hydroquinone or its breakdown products was detectable.

Ref.: 26

SCCS Comment

A positive control with hydroquinone (HQ) was not done before the samples, exposed to desoxyarbutin, were analyzed for their content of metabolites also seen in samples exposed to HQ. It was mentioned that no HQ values above the background noise were present, but the LOD for this substance or its metabolites was not given.

In vivo toxicokinetics or metabolism

There is no validated regulatory *in vivo* toxicokinetics or metabolism study in experimental animals available.

In an older exploratory screening study, the dermal penetration and metabolic fate of desoxyarbutin was investigated in pigmented guinea pigs. For comparison, hydroquinone (HQ) was investigated in parallel. Two 80% I-base creams were formulated with 5% desoxyarbutin in ethanol or 2.8% HQ in ethanol to yield final 0.05 M (1%, desoxyarbutin) or 0.05 M (0.56%) HQ in the creams. [¹⁴C]-Desoxyarbutin or [¹⁴C]-HQ was added to the creams (specific activity of 0.58 mCi/mL or 0.59 mCi/mL, respectively). During the 8-day study, the backs of the pigmented guinea pigs were depilated twice (days 1 and 3) and an area of 16 cm² was treated with 50 µl of each cream to each of 3 animals for four consecutive days. The urine was collected twice daily and stored at -20°C until analysis (scintillation counting, HPLC or thin layer chromatography (TLC). After the treatments were halted, the urines were collected until day 8 for a total of 167 hours. In addition, urine samples were collected from

a control guinea pig without any treatment. Prior to the analyses, the pH of the guinea pig urine was adjusted to 7 with HCl. The urine samples for TLC from desoxyarbutin or HQ treated animals prior to and after enzymatic digestion with β -glucuronidase and sulfatase were run on silica G plates. The spots were visualized with iodine vapour and the plates were scanned on a radioscanner for radioactivity measurements.

Results

Desoxyarbutin was excreted more rapidly than HQ, with a half-life ($t_{1/2}$) of about 9 h. After 38 hours about 97% was recovered in the urine. The respective values for HQ were $t_{1/2} > 167$ hours and recovery of about 52%. Little radioactivity (4%) was detected in the faeces in each case. Two major metabolites were detected in the urine from desoxyarbutin treated animals and identified as glucuronide ($\geq 57\%$) and sulfate ($\geq 29\%$). The obtained data showed also that the metabolic fate of desoxyarbutin in guinea pigs was different from that of HQ. Further analysis of the metabolism data revealed an effective permeability constant (K_{peff}) of 1.9×10^{-4} cm/h through guinea pig skin into the urine. The authors assumed that although this value represents an average flux through the entire animal, it is comparable to permeability constants determined from either steady state or finite dose skin penetration studies. A small amount (5%) of HQ/HQ-metabolites was also found in the urine of dA-treated animals. However, since the starting [^{14}C]-desoxyarbutin was contaminated, the presence of the HQ-metabolite was expected, and as the pH of the guinea pig urine had been adjusted to 7 for the enzymatic digestions, the presence of a $5 \pm 2\%$ HQ/HQ-metabolite is consistent with the amount of HQ contamination in the dosing solution and from the expected breakdown in the stored urine samples.

Finally, an exploratory study in guinea pigs showed that desoxyarbutin penetrated rapidly through the skin; it was glucuronidated and sulphonated and then rapidly excreted.

Reference: 39, 1

SCCS Comments

The data for the animals exposed to hydroquinone (HQ) are not given.

Applicants conclusion on toxicokinetics and metabolism

The hepatic metabolism of desoxyarbutin *in vitro* examined in hepatocytes from rabbits, rats, guinea pigs and human was shown to be fast and complete. Glucuronidation and sulphonation were demonstrated as the major metabolic pathways. Virtually no metabolism to hydroquinone or its breakdown products was detectable *in vitro*. The available study on skin penetration and metabolic fate of desoxyarbutin in guinea pigs is not in agreement with current guideline requirements and was not performed under GLP condition but can be considered as a scientifically valid screening study. This study indicated that desoxyarbutin penetrated rapidly through the skin, was glucuronidated and sulphonated, and then rapidly excreted.

Desoxyarbutin was found to have a different metabolic profile than hydroquinone (HQ) suggesting that HQ is not generated in the skin or systemically after topical application of desoxyarbutin.

SCCS comment

Data are available on the metabolism of desoxyarbutin in hepatocytes from several species; however data on its metabolism in (human) skin is lacking. Information from an *in vivo* study with topical application to guinea pigs indicates high dermal absorption and suggests extensive phase II metabolism of desoxyarbutin and about 5% breakdown to HQ in the dosing material.

3.3.10 Photo-induced toxicity

Combined phototoxicity and photoallergy study in guinea pigs

Guideline/method:	/
Species/strain:	Guinea pig/albino Crl: (HA)BR
Group size:	Photoirritation phase: 6 animals/group (9 males and 9 females in total)
Photoallergy phase:	5 – 10 animals/group (14 males and 11 females in total)
Test substance:	deoxyarbutin
Batch:	HT0059.05
Purity:	98.7%
Route:	Occlusive epicutaneous induction and challenge (Hill Top Chambers®)
Vehicle:	deoxyarbutin: Propylene glycol
Positive controls:	Acetone (photoirritation/-allergy phase)
Dose level:	Photoirritation phase: 1, 5, 20 and 50% in propylene glycol
Photoallergy phase:	50% in propylene glycol
Light source:	Bank of 8 fluorescent black light lamps (Sylvania F20BLB)
Irradiation:	10 J/cm ² UV-A (320 – 400 nm)
Negative control:	Propylene glycol
Positive controls:	Photoirritation phase: 0.01% 8-methoxypsoralen (8-MOP)
Photoallergy phase:	Musk ambrette (0.1% for challenge and 10% for induction)
GLP:	Yes
Date of report:	March 1996

The phototoxicity and photosensitising properties of deoxyarbutin were evaluated according to a modified protocol of Ichikawa et al., 1981, Gerberick and Ryan, 1989 and Nilsson et al., 1993 using male and female albino Crl:(HA)BR guinea pigs.

Photoirritation phase

Prior to application, the dorsal surfaces of the albino guinea pigs were depilated. Duplicate 0.3 ml applications of the test or control substances were applied to four sites per animal for 2 hours under occlusive conditions (Hill Top Chamber®, 25-mm diameter). The tested deoxyarbutin concentrations were 0, 1, 5, 20 and 50% in propylene glycol. The positive control was 0.01% 8-methoxypsoralen (8-MOP) in acetone. Thereafter, the patches were removed and the application sites wiped and covered with aluminium foil. The animals were exposed to 10 J/cm² of Ultraviolet-A (UV-A) light (320–400 nm). Following exposure, the foil was removed and the skin was examined 1, 4, 24, and 48 hours for dermal irritation and graded on a scale of 0 – 3 (0, no erythema; 1, slight but confluent or moderate patchy; 2, moderate; 3, severe with or without edema).

Photoallergy phase

Prior to the induction application, the nuchal region of the albino guinea pigs was shaved and depilated. The induction area was pre-treated with 4 intradermal injections of 0.1 ml of Freund's Complete Adjuvant (FCA) at each corner. Afterwards, the animals were tape stripped repeatedly to glisten the skin. The prepared skin areas were treated for 2 h with 0.3 ml of 50% deoxyarbutin in propylene glycol or 10% w/v musk ambrette in acetone as positive control via an adhesive patch (Hill Top Chamber®). The animals were kept in the restrainers and the skin was occluded. Thereafter, the patches were removed and the sites were wiped. The untreated lumbar regions were shielded and animals were exposed to 10 J/cm² of UVA light (320–400 nm). Induction was repeated on days 2, 4, 7, 9, and 11 with depilation performed on days 4, 7, and 11. Challenge was performed on day 22 on a naïve, depilated lumbar site by application of 0.3 ml/patch of the test material (50% deoxyarbutin) and positive control substance. The sites were occluded for 2 h followed by patch removal and wiping of the skin sites. The left challenge site and the induction areas were shielded with aluminium foil under tape (right challenge site uncovered) followed by exposure to 10 J/cm² of UVA light. Afterwards, the foil was removed and at 24 and 48 hours after challenge the skin was graded. The re-challenge control group remained untreated.

Results

Phototoxicity

There was no sign of dermal irritation to any of the test substance concentration on either the UVA irradiated or non-irradiated sites except for a very slight patchy erythema (grade 1) at two sites exposed to 1% deoxyarbutin (1 UV-A irradiated, 1 not irradiated) and one exposed to 50% deoxyarbutin and UV-A. However, compared to the reactions of the positive control, these very slight dermal findings were considered as not indicative for photoirritation. The positive control resulted in moderate to severe erythema at the UVA irradiated sites in all animals indicating the sensitivity and suitability of the test system.

Photoallergy

Grade 1 erythema at the UV-A irradiated challenge site was noted in 3/10 animals treated with 50% deoxyarbutin. These reactions were observed at 24 hour in 2/10 and at both 24 and 48 hour observations in 1/10 animals. One of the 10 challenge sites not receiving UV-A radiation also exhibited a grade 1 erythema at 24 and 48 h scoring observation. Two of five animals in the primary challenge control group showed a grade 1 erythema at the UV-A treated site. No signs of irritation were recorded at the sites without UV-A exposure. There were no relevant differences in the incidence or the severity of challenge reactions when comparing the test group sites receiving UV-A irradiation and those not receiving UV-A exposure. In addition, there were also no relevant differences observed between challenge reactions in the UV-A exposed sites in the test substance-treated groups and the primary challenge irradiation control groups. Musk ambrette as positive control substance was proven to be a photoallergen under the conditions of the study as an increased incidence and severity of skin reactions at the UV-A exposed sites occurred, demonstrating the suitability and sensitivity of the test procedure.

Conclusion

Deoxyarbutin was shown to have no phototoxic and no photoallergic potential when tested in concentrations up to 50% in propylene glycol under the conditions of this combined study in male and female guinea pigs.

Ref.: 43

SCCS comment

The test results indicate that deoxyarbutin is not phototoxic or photosensitising.

3.3.11 Human data

Human repeated insult patch tests (HRIPTs)

Guideline/Method:	Approved study protocol and standard operating procedures
Species:	Human
Group size:	229 induced volunteers and 208 completed (males and females)
Test substance:	deoxyarbutin
Batch:	509014
Purity:	99.8% (HPLC)
Route:	Dermal occlusive application by patch
Induction:	Applications on Monday, Wednesday and Friday for 24 hours for a total of 9 applications
Rest period:	about 2 weeks
Challenge:	1 application for 24 hours
Concentration:	6.0% deoxyarbutin in SC23 emulsion (O/W)
GLP:	Yes
Date of report:	May 2007

Deoxyarbutin was tested for potential irritation and sensitisation on human skin in a repeated insult patch test (HRIPT) as a 6% emulsion (O/W, SC23). Prior to the application, the test area was wiped with 70% isopropyl alcohol and allowed to dry. The test material emulsion was occlusively applied to the upper back (between the scapulae) of each of the

229 male and female healthy volunteers and was allowed to remain in direct skin contact for a period of 24 hours. Patches were applied to the same site on Monday, Wednesday, and Friday for a total of 9 applications during the induction period. The sites were graded for dermal irritation 24 hours after removal of the patches on Tuesday and Thursday and 48 hours after removal on Saturday.

Following a rest period of about 2 weeks, the challenge patches were applied to previously untreated skin sites for 24 hours. After removal of the patches, the sites were evaluated for dermal findings and 48 and 72 hours thereafter.

Results

208 male and female volunteers completed the study and 21 discontinued, but not due to test material reaction. During the induction phase and after challenge, no visible skin reaction was noted in any of the volunteers at any time point.

Conclusion

Under the conditions of the repeated insult patch test, no skin reactions were noted in any of the 208 male and female volunteers. Thus, deoxyarbutin investigated as a 6.0% O/W emulsion did not demonstrate any potential for skin irritation or sensitisation in humans.

Ref.: 24

This study result is in line with a previously performed HRIPT in 99 male and female volunteers, of which 94 volunteers completed the study. Deoxyarbutin was tested as a 3% moisturiser cream formulation containing 0.3% Glydant under comparable occlusive conditions as described above. The moisturizer cream without deoxyarbutin was tested in parallel as vehicle control. Among the 94 volunteers who completed the study, there was 1 female showing skin reactions indicative for sensitisation during late induction and after challenge. This female had a history of stress asthma and indicated by re-questionnaire that she was allergic to a penicillin type and has to avoid certain perfumes. Two re-challenges indicated that deoxyarbutin was not the causative agent for the dermal findings. Finally, it can be concluded that deoxyarbutin investigated as a 3.0% moisturizer cream showed no clear indication for skin irritation or skin sensitisation under the conditions of this human repeated insult patch test.

Ref.: 42

SCCS comment

The SCCS does not consider HRIPT studies for determining sensitisation potential to be ethical.

Other Human tests

The efficacy of deoxyarbutin as a skin lightening substance in humans was investigated in two studies which are reported here in brief for the sake of completeness and with regard to notable undesirable effects.

50 female volunteers (34 Caucasians and 16 mixed ethnic persons) received application of a 3% deoxyarbutin containing moistening cream including a placebo control, each on a 100 cm² area on the dorsal surface of the forearm. The daily treatment was for 12 weeks from mid-November to mid-February at a clinical site in the United Kingdom. No signs of skin irritation were reported during the course of this study.

Ref. 1

A further human clinical trial was performed with 25 male and female volunteers with Fitzpatrick skin types of III or IV. Three skin sites on the back of each volunteer were exposed for 10-20 min daily for 7 consecutive days to UV light from a tanning bed. At the end of the tanning regime, one of each of the coded test sites was left untreated, treated with 3% deoxyarbutin or treated with 4% hydroquinone. The test substance preparations were topically applied 3 times per week for 5 weeks, at 12.5 µL / 2 cm² in moisturizer (oil-

in-water emulsion type), using an occlusive patch system and modified to a semi-occlusive system when necessary to manage irritation. After the 5-week treatment period, the percent of tan remaining in the untreated and treated sites was compared. Other endpoints or side effects were not reported.

Ref. 30

3.3.12 Special investigations

***In vitro* studies**

The effects of deoxyarbutin (dA) and hydroquinone (HQ) on cultured human cells (primary cultures of human melanocytes, keratinocytes and fibroblasts established from neonatal foreskin of dark and light skin individuals) were compared in assays for viability (cell counts), tyrosine hydroxylase activity and melanin content: The maximum concentration of dA that allowed 95% viability was 4-fold higher than HQ in human keratinocytes, indicating that dA is less cytotoxic than HQ. At the maximum concentration allowing normal cellular viability, dA effectively inhibited tyrosinase activity and melanin content in human melanocytes, where HQ was marginally inhibitory. Upon removal of dA, the tyrosinase activity and melanin content was normalised within 5 days (ref. 30). Apparently, dA inhibits human tyrosine hydroxylase and DOPA oxidase in a reversible manner and is a more robust competitive inhibitor than HQ (Chawla et al. 2008). Further studies in cultured melanocytes showed that deoxyarbutin not only inhibited tyrosinase, but also decreased the protein expression (Hu et al. 2009).

Tests in experimental animals

Two studies, conducted to assess efficacy of deoxyarbutin as a skin lightening substance, are briefly reported for completeness, but only with respect to undesirable effects. Hairless pigmented guinea pigs were treated 9 weeks with 3% deoxyarbutin containing cream and for comparison with hydroquinone, kojic acid and arbutin containing creams. The deoxyarbutin-treated sites showed no signs of skin irritation.

Ref. 1

Efficacy was also examined in human xenografts on female ICD-SCID mice: the grafts were left untreated for 2 months until hyperpigmentation was reached, then topical treatment with 5% deoxyarbutin or HQ or tert-butylphenol containing emulsions was started. Also the dose-response (0.1, 0.3, 1, 3%) and reversibility (8 weeks after termination of treatment) were studied. No signs of inflammation or abnormal morphology were noted.

Ref. 30

3.3.13 Information on the toxicity of hydroquinone

Taken in part from the SCCP/1158/08 Opinion and updated in SCCS/1550/2015

LD₅₀-oral-rat = 298 mg/kg

Slightly irritating to the eye

Sensitising to the skin

NOEL (28d/90d-oral-rat) = 20 mg/kg/day

NOAEL (28d/90d-dermal-rat) = 74 mg/kg/day

NOEL (developmental toxicity-rabbit) = 25 mg/kg/day (dams)

NOEL (developmental toxicity-rabbit) = 75 mg/kg/day (teratogenic effects).

NOEL (1-generation reproduction toxicity-rat) = 15 mg/kg/day (general toxicity).

NOEL (1-generation reproduction toxicity-rat) = 150 mg/kg/day (reproductive toxicity).

Negative in the Ames test, the dominant lethal assay and the mouse spot test.

Positive in the *in vitro* chromosome aberration test (+S9)

Positive (i.p.) and weakly positive (oral) in the *in vivo* micronucleus test.

Equivocal conclusions on potential carcinogenic effects at dosage levels ≥ 25 mg/kg/day.

[HQ Refs. A, B]

Hydroquinone has been used for many years in skin-bleaching preparations up to 2%. It does not directly bleach the skin, but acts through competitive inhibition of tyrosinase resulting in gradual fading of hyperpigmented spots by a reduction in the formation of new pigment.

With regard to potential adverse effects caused by hydroquinone, covalent binding and oxidative stress are mechanisms postulated to be induced by the molecule. Oxidised hydroquinone metabolites may covalently bind cellular macromolecules or alkylate low molecular weight nucleophiles (e.g. glutathione) resulting in enzyme inhibition, alterations in nucleic acids and oxidative stress. Cell proliferation associated with nephrotoxicity in a sensitive strain of animals (male F344 rat) has been postulated to be involved in the production of renal tumours in rats.

[HQ Ref. A]

According to IARC, hydroquinone is not classifiable as to its carcinogenicity to humans. This conclusion was based upon limited evidence in experimental animals and inadequate evidence in humans (IARC 1999). In the EU, hydroquinone is classified as Carc Cat 2 H351 (suspected of causing cancer) based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI¹.

A more recent literature review on the carcinogenicity of hydroquinone concludes that indeed renal tumours were observed in male rats, but that the mode of action (exacerbated chronic progressive nephropathy) appears to be a rat-specific disease that appears to lack a human counterpart. The available cohort studies (all involving occupational exposure) failed to show a clear causal relationship between exposure to hydroquinone and the development of several types of malignancies.

[HQ Ref. C]

A final side effect linked to the use of hydroquinone as a skin bleaching agent is ochronosis, the darkening of the skin accompanied by changes in the papillary dermis. Recently a literature review from 1966 to 2007 on the topic of human exposure to topically applied pharmaceutical hydroquinone preparations was published. Data on more than 10,000 patients were screened. Applied hydroquinone concentrations ranged from 1 to 30% and the duration of exposure from 1 day to 20 years. More than 9,500 patients used hydroquinone for a period longer than one month. In total, 789 cases of ochronosis were reported, of which 756 arose in Africa.

When hydroquinone is used at relatively high concentrations (>2%) in the medicinal world to treat for example dyschromia, a risk-benefit analysis is performed.

[HQ Ref. D]

The Cosmetic Ingredient Review (CIR) Expert Panel conducted a safety assessment of hydroquinone as used in cosmetics and concluded that it is safe at concentrations ≤ 1% in hair dyes and is safe for use in nail adhesives. Hydroquinone should not be used in other leave-on cosmetics. With regard to the use of HQ in topical formulations as skin bleaching and depigmenting agent, the CIR report of 2010 points out that this use is considered in the USA as drug use and thus falls under the purview of the FDA. Prescription and over-the-counter-products range in concentration from 0.4 to 5% (Anderson et al. 2010). [HQ Ref. E]

Studies on the kinetics (ADME) of hydroquinone (HQ) in humans and rodents (reviewed by McGregor 2007=HQ Ref.C and Anderson et al. 2010=HQ Ref.E) indicate rather high bioavailability and rapid clearance after oral or dermal administration. The dermal penetration in humans was examined for 2% HQ in cream *in vitro* and *in vivo* with similar results [Wester et al. 1998=HQ Ref. F]: Total permeation of HQ after 24h was 43.3% of the

¹ The SCCS is aware that HQ is presently evaluated under REACH, and further data is requested on its *in vivo* oral genotoxicity (<http://echa.europa.eu/documents/10162/7e36b2f6-80c6-42fb-9d67-7f7c7a86ee10>)

dose *in vitro*; flux was 2.93 µg/h-cm². An average of 45.3±11.2% of the dose was recovered in the urine of volunteers after application of HQ to forehead skin.

For the safety evaluation of HQ exposure resulting from the use of skin bleaching products in comparison to internal HQ doses which may induce ochronosis, the SCCS will use 50% dermal absorption for HQ.

3.3.14 Safety evaluation (including calculation of the Margin of Safety)

Safety evaluation for deoxyarbutin (3% in face cream, applied once per day)

Application of face cream (1.54 g/day, according to the SCCS NoG, Table 3) with 3% a.i. equals 46.2 mg deoxyarbutin/person/day; adjusted to 60 kg b.w. = 0.77 mg/kg x day. For calculation of a margin of safety, the NOAEL of a subchronic dermal study (ref. 40) is divided by the human external dose.

90-day dermal rabbit toxicity study for deoxyarbutin:		
NOAEL for systemic toxicity (mg/kg bw)		about 800
Human external dose	(mg/kg bw)	0.77
MOS: 800 / 0.77 = 1039		

*NOTE: An additional MOS calculation - based on the systemic exposure dose (SED) for deoxyarbutin using the mean+2 SD, i.e. 80.04% or 134 µg/cm² from the *in vitro* dermal penetration study (ref. 27) and the NOAEL of 316 mg/kg bw from the 28-day oral toxicity study in rats (ref. 18) - arrives also at a sufficient margin of safety (of 250). The oral NOAEL is considered as worst-case scenario for deoxyarbutin since the acidic stomach environment will lead to its degradation to hydroquinone which then causes the observed toxicity.*

Safety evaluation for the Hydroquinone (HQ) formed

Other than alpha- or beta-arbutin (SCCS/1550/2015 and SCCS 1552/2015) where partial hydrolysis of the absorbed fraction can occur within the skin, the dermally absorbed deoxyarbutin undergoes apparently extensive phase-II metabolism with no measurable release of hydroquinone in skin. However, hydroquinone can be present as impurity in the cosmetic product itself as a consequence of partial degradation of deoxyarbutin.

Considerations on the stability of deoxyarbutin with regard to formation of HQ as impurity in the cosmetic preparations:

Deoxyarbutin seems to be stable in anhydrous emulsions or in O/W formulations at pH 7 when stored at low temperatures (8°C) and protected from light (Lin et al. 2011). However, under real use conditions (elevated temperatures on skin and pH of about 5.5), some degradation to hydroquinone (HQ) can occur. The extent of HQ formation under real use conditions on human skin has not been studied.

Approximations are derived from *i)* stability tests in solution which show at slightly acidic pH some decline in the content of deoxyarbutin with a corresponding increase in HQ: already at 1 hour HQ content was 0.03% at pH 6 and 0.25% at pH 5; after 12 hours the HQ content was 0.2% at pH 6 and 2.42% at pH 5 (ref. 29, page 19). *ii)* The kinetic study in guinea pigs with dermal application of deoxyarbutin in I-base cream reported "contamination" of the starting material with about 5±2% HQ, and this was also reflected by the presence of a similar fraction of HQ/HQ metabolites in urine samples (ref. 39).

In the absence of other data, the SCCS assumes 10% HQ as impurity in deoxyarbutin under in use conditions.

Estimates:

Application of 1.54 g/day cream with 3% desoxyarbutin (dA) equals 46.2 mg dA/person/day:
 If 10% of the initial ingredient (dA) degraded to HQ, the external exposure amounts to 4.62 mg (dA) and corrected for molecular weights of dA (194.23) and HQ (110.11),
 $(4.62 \times 110.11/194.23) = \mathbf{2.62 \text{ mg HQ per person/day}}$.

As HQ is known to readily penetrate the skin (dermal absorption about 50%), the presence of this impurity in the product would result in **internal HQ dose of 1.31 mg/day**
 and (: 60 kg) **SED for HQ of 0.0281 mg/kg bw/day**.

The estimated exposure to hydroquinone (HQ) from application of desoxyarbutin containing cosmetic products is assessed below and compared to risks related to a) repeated dose toxicity, b) induction of ochronosis, and c) carcinogenicity.

a) HQ repeated dose toxicity

In this part of the safety assessment, MOS values are calculated from literature data on **sub/-chronic toxicity** tests with hydroquinone (see section 3.3.13)

NOAEL (90 day oral - rat):	20 mg/kg bw/day
NOAEL (1-generation reprotox - rat)	15 mg/kg bw/day
SED for HQ:	0.0218 mg/kg bw/day

→ **MOS (NOAEL/SED)** values would be
917 (90 day) or **688** (reprotox)

b) HQ induction of ochronosis

HQ is also suspected to cause exogenous **ochronosis** (EO). As a NOAEL has not been established for exogenous ochronosis, the lowest effect level described in a case report was used to calculate the Exposure Dose of HQ that might cause ochronosis: 1% has been adopted as the minimum exposure level of HQ causing EO since no publication available suggests EO with products formulated with 1% or less HQ.

Exposure dose of HQ that may cause ochronosis was calculated as **8 mg / day**:

[1 x 0.8 x 1000 x 2 x 50 / 100 x 100]	
Lowest concentration in HQ-induced ochronosis:	1 %
Maximum quantity of application:	0.8 g formulation
Frequency of application per day:	2
Absorption of HQ through skin	50 %

total estimated HQ amount resulting from desoxyarbutin skin application:
of 1.31 mg HQ per day in skin (internal amount)

compared to the HQ internal (skin) amount resulting from 1% HQ crème:
≈ 8 mg (for 50% dermal HQ absorption)
 → **SED Ratio of 6.1**

The minimum exposure level of HQ which may cause ochronosis is calculated as being only 6 times higher than the estimated exposure resulting from application of 3% desoxyarbutin formulations with 10% HQ as impurity.

c) Carcinogenicity

In the EU, hydroquinone is classified as Carc Cat 2 H351 (suspected human carcinogen) Muta Cat 2 H341 (suspected of causing genetic defects) based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI.

The SCCS has carried a calculation to determine lifetime cancer risk (as in section 3-7.4 of the Notes of Guidance SCCS): First an animal dose descriptor (T25) for carcinogenic

potency is determined and then converted to a human dose descriptor (HT25) based on comparative metabolic rates by using the following formula:

$$\text{HT25} = \frac{\text{T25}}{(\text{body weight}_{\text{human}} / \text{body weight}_{\text{animal}})^{0.25}}$$

For the critical effect (renal tubular cell adenomas in male F344 rats; NTP study 1989), the **T25 dose descriptor** for hydroquinone is **61.4 mg/kg bw/day**.

From this a **HT25 value of 18.2 mg/kg bw/d** was obtained.

Assuming a systemic exposure dose of **0.0218 mg/kg bw/d**, the risk is calculated to be about **3 x 10⁻⁴**.

$$\text{Lifetime cancer risk} = \frac{\text{SED}}{\text{HT25} / 0.25}$$

Whilst it can be taken into account that this tumour type is considered rodent specific and may have little relevance for humans, the lifetime risk calculated by linear extrapolation (in this case a very conservative approach), would exceed the usually accepted risk limits.

Moreover, the estimated systemic HQ exposure from the use of deoxyarbutin-containing cosmetic products (0.0281 mg/kg bw/d) would be higher than oral intake of HQ with food (0.017 mg/kg bw/d; Deisinger et al. 1996).

3.4 Discussion

Physico-chemical properties

The applicant reports that deoxyarbutin is stable for at least 2 years when protected from humidity, temperatures above 8°C and light. However, deoxyarbutin is not stable in slightly acidic medium and hydrolyses to hydroquinone at room temperature [29]. This is of relevance when it is used in cosmetic products on skin (which has a slightly acidic pH), and when there is exposure to higher temperatures and light. Therefore, under in use conditions, it has to be considered that deoxyarbutin can undergo hydrolysis into hydroquinone.

An approximation of the possible HQ content in deoxyarbutin formulations was derived from stability tests in solution and the reported "contamination" of the starting material with about 5±2% HQ in I-base cream applied in a kinetic study with guinea pigs. In the absence of other data, the SCCS assumes 10% HQ as impurity in deoxyarbutin under in use conditions.

Acute toxicity

The acute oral and dermal toxicity of deoxyarbutin can be regarded as low. Studies performed according to current testing guidelines under GLP conditions with characterised test material resulted in LD₅₀ values for acute oral and dermal toxicity of > 2000 mg/kg bw in rats. Former acute oral, dermal and intraperitoneal studies with limited validity generally confirmed the low acute toxicity for all application routes in the species tested.

Skin and mucous membrane irritation

Deoxyarbutin did not exhibit any corrosive potential to the skin in the *in vitro* TER test and was shown to be non-irritating to the intact skin of New Zealand White rabbits. In an eye irritation test using New Zealand White rabbits, it was slightly and transiently irritating to the eyes, but threshold scores for classification as an eye irritant were not reached. However, as redness and particularly chemosis were observed during the observation

period, the test substance is considered as a mild eye irritant. A standard cream formulation containing 3% desoxyarbutin led to no signs of eye irritation in rabbits, but the low volume of test formulation (about 10 µl, i.e. 1/10 of the volume recommended in the OECD TG 405) used in this study precludes an evaluation of the eye-irritating potential of the test formulation. Human repeated insult patch tests did not reveal a skin-irritating potential for desoxyarbutin at a concentration of up to 6.0%.

Skin sensitisation

The sensitising potential of desoxyarbutin was investigated in two murine local lymph node assays. The more recent study investigated concentrations of 10% - 50% and was carried out in accordance of the actual OECD and EC guidelines. The former study investigated concentrations of 3% - 20%, but a slightly higher number of animals and exposure days as well as individual lymph node measurements were used. The local lymph node assays performed indicate that desoxyarbutin is a moderate skin sensitizer.

Dermal/percutaneous absorption

The human *in vitro* percutaneous absorption study performed under current guideline requirements and under GLP conditions showed that after dermal application of 3% desoxyarbutin in a standard o/w emulsion (160.81 µg desoxyarbutin/cm²) applied for 24 hours to the viable skin of three female donors, desoxyarbutin was detected in all compartments relevant to assess dermal absorption and penetration. The recovery revealed no indication for degradation of the test material. A high dermal availability of 58.12±11.96 %, corresponding to 93.66±20.15 µg desoxyarbutin/cm² was observed. Because of some limitations in the *in vitro* study (low number of donors), the SCCS considers to use the mean+2 SD, i.e. 80.04% or 134 µg/cm² for dermal penetration in the safety assessment.

Repeated dose toxicity

The systemic toxicity after repeated oral application to male and female rats for 28 days was low and effects could only be observed at the current internationally accepted limit dose level of 1000 mg/kg bw consisting of transient clinical findings, slightly reduced food consumption and retarded bodyweight gain, minor haematological effects in females and slight impairment of single clinical chemistry parameters. The relative liver weights of both sexes and the relative kidney weights of the males were increased but without any histopathological correlation. The functional observation battery revealed no indication of any neurological impairment at any dose level. The No-Adverse-Effect-Level (NOAEL) for subacute toxicity in rats after 28-day oral treatment was 316 mg/kg bw. This value may be considered as the worst-case scenario for desoxyarbutin since the acidic stomach environment will lead to its degradation to hydroquinone which then causes the observed toxicity. Also in light of the pronounced route effect observed in the *in vivo* genotoxicity tests (see 3.3.6.), the SCCS concluded that the oral application route should be considered as inappropriate for investigating safety of desoxyarbutin in the context of its dermal application, and therefore chose the subchronic dermal toxicity study to derive a NOAEL for the calculation of a margin of safety. **Repeated dermal** application of desoxyarbutin in **rabbits** either as 3% cream formulation for 28 days or as 1, 5 and 40% propylene glycol/ethanol solution for 91 days did not lead to any substance-related systemic findings up to the highest dose level investigated. The respective **NOAEL** for systemic toxicity in rabbits was 40% desoxyarbutin corresponding to about **800 mg/kg bw**. This value will be used for risk assessment and the calculation of the margin of safety (MoS).

Mutagenicity/Genotoxicity

Overall, the genotoxicity of desoxyarbutin is sufficiently investigated in valid genotoxicity tests for the 3 endpoints of genotoxicity: gene mutations, chromosome aberrations and aneuploidy.

Desoxyarbutin did not induce gene mutations in bacteria. In human lymphocytes desoxyarbutin showed a clastogenic potential with and without metabolic activation. However, as the clastogenic reactions were observed with and without metabolic activating enzymes, and desoxyarbutin is known to be unstable at lower pH values, chemical hydrolysis

to hydroquinone can have occurred to a certain extent. Then, instead of desoxyarbutin, its chemical breakdown product hydroquinone, a known clastogenic and cytotoxic agent *in vitro* and *in vivo*, may have been the causative agent. The positive *in vitro* results on clastogenicity were not confirmed in two separate micronucleus tests with desoxyarbutin under the standard application procedure of intraperitoneal injection. In contrast, orally applied dose levels of desoxyarbutin induced micronuclei in the polychromatic erythrocytes of the bone marrow of male and female mice. This was expected due to the chemical breakdown of desoxyarbutin to hydroquinone in the acidic stomach environment. Thus, the oral application route to investigate the possible genotoxic or clastogenic potential of desoxyarbutin should be considered as inappropriate in the context of safety evaluation of the dermally applied substance. Desoxyarbutin did not induce an increase in the number of spermatogonial cells with structural or numerical chromosome aberrations. However, due to lacking indications of exposure of the spermatogonial cells, this test has limited value. Based on the present reports, the parent compound desoxyarbutin can be considered to have no *in vivo* genotoxic potential and additional tests are unnecessary. Arbutins are considered to be metabolised differently by different glycosidases or by spontaneous hydrolysis, yet they all form hydroquinone (HQ). The latter is considered as the genotoxic moiety; therefore a read-across based on HQ release is a possibility to assess the genotoxic potential of the arbutins as a group.

Reproduction toxicity

Developmental and reproductive toxicity studies were not submitted.

The repeated oral application of desoxyarbutin for 28-days in rats up to the limit dose level of 1000 mg/kg bw as well as the repeated dermal application in rabbits for up to 3 months and the highest tested concentration of 40% (corresponding to about 800 mg/kg bw) led to no indication of any impairment of male or female reproductive organs.

Toxicokinetics and metabolism

The hepatic metabolism of desoxyarbutin *in vitro*, examined in hepatocytes from rabbits, rats, guinea pigs and humans, was shown to be fast and complete. Glucuronidation and sulphonation were demonstrated as the major metabolic pathways. No metabolism to hydroquinone or its breakdown products was detectable *in vitro*. Whilst information on the hepatic metabolism of desoxyarbutin is available, data on its metabolism in human skin is lacking.

The available screening study on skin penetration and metabolic fate of desoxyarbutin in guinea pigs indicated high absorption of desoxyarbutin that penetrated rapidly through the skin; it was glucuronidated and sulphonated, and then rapidly excreted.

Desoxyarbutin was found to have a different metabolic profile than hydroquinone (HQ), suggesting that HQ may not be generated in the skin or systemically after topical application of desoxyarbutin. This was supported by the fact that in a dermal penetration study *in vitro* using human skin, the recovery revealed no indication for degradation of the test material. Information from an *in vivo* study with topical application to guinea pigs suggests extensive phase II metabolism of desoxyarbutin. However, in the same study about 5±2% breakdown to hydroquinone (HQ) in the dosing material was reported. Therefore, (nonenzymatic) degradation to HQ under in use conditions has to be considered as well (see also above section 'Physico-chemical properties').

Photo-induced toxicity

Desoxyarbutin was shown to have no photoirritation and no photoallergic potential when tested in concentrations up to 50% in propylene glycol under the conditions of a combined study in male and female guinea pigs.

Human data

Two independent human repeated insult patch tests showed that desoxyarbutin up to a concentration of 6.0% did not demonstrate any potential for skin irritation or sensitisation in humans.

4. CONCLUSION

1. *Does the SCCS consider, on the basis of the provided scientific data, the use of desoxyarbutin to be safe for consumers in cosmetic products in a concentration up to 3% in face creams?*

Although on the basis of the provided scientific data the use of desoxyarbutin as such can be considered safe for consumers in cosmetic products in a concentration up to 3% in face creams, hydroquinone will be formed at levels which raise concerns with regard to the safety of such products during life-cycle of the product (e.g. storage conditions and stability under in-use conditions). Therefore, the overall conclusion of the SCCS is that the use of desoxyarbutin up to 3% in face creams is not safe.

2. *And/or does the SCCS have any scientific concerns with regard to the use of desoxyarbutin or related substances known to release hydroquinone in cosmetic products?*

/

5. MINORITY OPINION

/

6. REFERENCES

References included in submission

Note: „Deoxyarbutin 100“=code for the company's compound name

1. Boissy RE, Visscher M, DeLong MA (2005) Deoxyarbutin: A novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency, *Experim. Dermatology*, 14, 601-608
2. Bradley MO, Taylor VI, Armstrong MJ, Galloway SM (1987) Relationships among Cytotoxicity, Lysosomal Breakdown, Chromosome Aberrations, and DNA Double-strand Breaks, *Mut. Res.*, 189, 69-79
3. ECB (European Chemicals Bureau, 2000) IUCLID Dataset, Hydroquinone (CAS 123-31-9), 18 February 2000 (<http://ecb.jrc.it/IUCLID-DataSheets/123319.pdf>)
4. Girindus AG (2005a) „Deoxyarbutin 100“: Acute oral toxicity study with rats (acute toxic class method), Report ARC-L-1632, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, August 2005
5. Girindus AG (2005b) „Deoxyarbutin 100“: Acute dermal toxicity study with rats, Report ARCL-1625, Environmental and Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, August 2005
6. Girindus AG (2005c) „Deoxyarbutin 100“: In vitro skin corrosion study – Transcutaneous electrical resistance test, Report ARC-L-1489, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, May 2005

7. Girindus AG (2005d) „Deoxyarbutin 100“: Acute dermal irritation/corrosion study with rabbits, Report ARC-L-1633, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, August 2005
8. Girindus AG (2005e) „Deoxyarbutin 100“: Acute eye irritation/corrosion study with rabbits, Report ARC-L-1634, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, August 2005
9. Girindus AG (2005f) „Deoxyarbutin 100“: Skin sensitization study (Local lymph node assay), Report ARC-L-1797, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
10. Girindus AG (2005g) „Deoxyarbutin 100“: Vapour pressure, Report ARC-L-1843, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
11. Girindus AG (2005h) „Deoxyarbutin 100“: Relative density, Report ARC-L-1842, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
12. Girindus AG (2005i) „Deoxyarbutin 100“: Boiling Temperature, Report ARC-L-1841, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
13. Girindus AG (2005j) „Deoxyarbutin 100“: Melting Temperature, Report ARC-L-1840, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
14. Girindus AG (2005k) „Deoxyarbutin 100“: Water solubility, Report ARC-L-1845, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
15. Girindus AG (2005l) „Deoxyarbutin 100“: Partition coefficient, Report ARC-L-1846, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
16. Girindus AG (2005m) „Deoxyarbutin 100“: Relative Self-Ignition Temperature, Report ARC-L- 1851, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, December 2005
17. Girindus AG (2005n) Prüfanweisung (PA) Deoxyarbutin 100 [Test Instruction Deoxyarbutin 100, K WP PA 1965] Report No. F30123 K WP PA 1965/03, Girindus AG, Halle, Germany, unpublished data, 01 December 2005
18. Girindus AG (2006a) „Deoxyarbutin 100“: 28-day oral toxicity study with rats, Report ARC-L- 1876, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, January 2006
19. Girindus AG (2006b) „Deoxyarbutin 100“: In vitro mammalian cytogenetic study (chromosome analysis), Report ARC-L-1883, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, January 2006
20. Girindus AG (2006c) „Deoxyarbutin 100, Batch No. 509014“: Micronucleus test with mice, Report ARC-L-1930, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, February 2006
21. Girindus AG (2006d) „Deoxyarbutin 100, Batch No. 504007“: Micronucleus test with mice, Report ARC-L-1929, Life Science, Toxicology, ARC Seibersdorf Research GmbH, Seibersdorf, Austria, unpublished data, February 2006
22. Girindus AG (2006e) Material Safety Data Sheet, Deoxyarbutin 100, Version 007/2006, Girindus AG, Bensberg, Germany, 21 February 2006
23. Girindus AG (2007a) Mammalian erythrocyte micronucleus test, Deoxyarbutin 100, BioReliance Study No. AB37AG.123.BTL, Sponsor Project No. 11430, BioReliance, Rockville, MD, USA, unpublished data, 25 January 2007
24. Girindus AG (2007b) Repeated insult patch test, O/W emulsion SC23 (6% dA 100), Project No. BLL-06-063, QC control No. Q-No 104544, CRL Study No. CRL17307, Clinical Research Laboratories, Piscataway, NJ, USA, unpublished data, 14 May 2007
25. Girindus AG (2007c) Mammalian spermatogonial chromosome aberration test, Deoxyarbutin 100, BioReliance Study No. AB37AG.109.BTL, Sponsor Project No. 12811, BioReliance, Rockville, MD, USA, unpublished data, 19 October 2007

26. Girindus AG (2007d) A study to determine the metabolism of deoxyarbutin in female cryopreserved rabbit, rat guinea pig and human hepatocytes, CXR Study No. CXR0548, CXR Bioscience Ltd., DUNDEE DD1 5JJ, Scotland, UK, unpublished data, 04 October 2007
27. Girindus AG (2007e) In vitro permeation and penetration properties of Deoxyarbutin 100 on human skin under GLP conditions, GLP Study Report STP 037/00, Report No. C-13120-152-0807, Across Barriers GmbH, Saarbruecken, Germany, unpublished data, 20 December 2007
28. Girindus AG (2007f) Product Profile Deoxyarbutin 100, Revision 07-26.2007, Girindus AG, Bensberg, Germany, unpublished data, 26 July 2007
29. Girindus AG (2007g) Stabilitätsbericht (SB) Deoxyarbutin 100 [Stability report of Deoxyarbutin 100], Report No. F30123 K WP SB 3290/01, Girindus AG, Halle, Germany, unpublished data, 17 December 2007
30. Hamed SH, Sriwiriyanont P, DeLong MA, Visscher MO, Wickett RR, Boissy RE (2006) Comparative efficacy and safety of a new tyrosinase inhibitory agent, deoxyarbutin, - J Cosmet Sci 57(4):291-308
31. OECD SIDS, Hydroquinone, UNEP Publications. (<http://www.inchem.org/documents/sids/sids/123319.pdf>)
32. Scott D, Galloway SM, Marshall RR, Ishidate M, Brusick D, Ashby J, Myhr BC (1991) Genotoxicity under Extreme Culture Conditions, A Report from ICPEMC Task Group 9, Mut. Res., 257, 147-205
33. The Proctor & Gamble Company (1994a) An acute oral toxicity study in rats with HT0059.01 and HT0060.01, SLS Study No. 3029.1886, Springborn Laboratories, Life Science Division, Spencerville, OH, USA, unpublished data, 20 July 1994
34. The Proctor & Gamble Company (1994b) An acute oral toxicity study in rats with HT0059.04, SLS Study No. 3029.1912, Springborn Laboratories, Life Science Division, Spencerville, OH, USA, unpublished data, 04 October 1994
35. The Proctor & Gamble Company (1994c) An acute dermal toxicity study in rats with HT0064.01, SLS Study No. 3029.1894, Springborn Laboratories, Life Science Division, Spencerville, OH, USA, unpublished data, 13 June 1994
36. The Proctor & Gamble Company (1994d) Up and down procedure for testing acute intraperitoneal toxicity in rats, SLS Study No. 3029.1887, Springborn Laboratories, Life Science Division, Spencerville, OH, USA, unpublished data, 28 June 1994
37. The Proctor & Gamble Company (1994e) A low volume eye irritation study in rabbits with HT0061.01, SLS Study No. 3029.1895, Springborn Laboratories, Life Science Division, Spencerville, OH, USA, unpublished data, 03 May 1994
38. The Proctor & Gamble Company (1994f) Murine local lymph node assay, IITRI Project No. L08321, Study No. 45, IIT Research Institute, Life Science Research, Chicago, IL, USA, unpublished data, June 1994
39. The Proctor & Gamble Company (1994g) The penetration and metabolic fate of the topically applied skin lightening active deoxyarbutin in Guinea pigs, Research and Development Department Report, Cosmetic and Fragrances Technology Division, The Proctor & Gamble Company, Cincinnati, OH, USA, unpublished data, 31 August 1994
40. The Proctor & Gamble Company (1994h) 28-day and 91-day dermal toxicity study in rabbits, IRDC Study No. 191-1600, DRD No. HTSE-042, IRDC, Mattawan, MI, USA, unpublished data, 17 October 1994
41. The Proctor & Gamble Company (1994i) Salmonella/Mammalian microsome (Ames Test) and Escherichia coli WP2 mutagenesis assay, HT0059.01, Document No. HTSE-040, Laboratory Study No. TE257.508, Microbiological Associates, Rockville, MD, USA, unpublished data, 22 March 1994
42. The Proctor & Gamble Company (1995a) Human repeat insult patch test (HRIPT), HT0072.01, deoxyarbutin (3%) in a moisturizer vehicle with 0.3% Glydant, DRD No. HTSE-051, Report No. 03694, IS Consulting Limited, Haddington, Scotland, unpublished data, April 1995
43. The Proctor & Gamble Company (1996a) Photoirritation/Photoallergy study of HT0059.05 in Guinea pigs, DRD No. HTSE 054, Report No. CHW 51002116, Corning Hazleton Inc.

Additional References – added by the SCCS

- Chawla S, deLong MA, Visscher MQ, Wickett RR, Manga P, Boissy RE (2008) Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives. *Brit J Dermatol* 159 (6) 1267-1274
- Deisinger PJ, Hill TS, English JC (1996) Human Exposure to Naturally Occurring Hydroquinone, *J Toxicol Environ Health*. 47, 31-46.
- Hu ZM, Zhou Q, Lei TC, Ding SF, Xu SZ (2009) Effects of hydroquinone and its glucoside derivatives on melanogenesis and antioxidation: Biosafety as skin whitening agents. *J Dermatol Sci* 55(3) 179-84
- Lin CC, Yang CH, Chang NF, Wu PS, Chen YS, Lee SM, Chen CW (2011) Study on the stability of Deoxyarbutin in an anhydrous emulsion system. *Int J Mol Sci* 12, 5946-5954
- Yang CH, Chen YS, Lai JS, Hong WW, Lin CC (2010) Determination of the thermodegradation of deoxyArbutin in aqueous solution by high performance liquid chromatography. *Int J Mol Sci* 11(10):3977-3987. doi: 10.3390/ijms11103977
- Yang CH, Chang NF, Chen YS, Lee SM, Lin PJ, Lin CC (2013) Comparative study on the photostability of arbutin and deoxy-arbutin: sensitivity to ultraviolet radiation and enhanced photostability by the water-soluble sunscreen, benzophenone-4. *Biosci Biotechnol Biochem* 77(5):1127-1130

References in section 3.3.13 on Hydroquinone [HQ Ref. A-F]

- OECD SIDS. Hydroquinone, CAS No. 123-31-9 (above Ref. 31)
- International Programme on Chemical Safety, IPCS (1994). Environmental Health Criteria 157, Hydroquinone, WHO, Geneva
- McGregor D (2007) Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. *Crit Rev Toxicol* 37(10):887-914.
- Levitt J (2007) The safety of hydroquinone: a dermatologist's response to the 2006 Federal Register. *Journal of the American Academy of Dermatology* 57(5):854-872.
- Andersen FA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW [Cosmetic Ingredient Review (CIR) Expert Panel] (2010) Final amended safety assessment of hydroquinone as used in cosmetics. *Intl J Toxicol*. 29 (suppl 4): 274S-287S
- Wester RC et al. (1998) Human *in vivo* and *in vitro* hydroquinone topical bioavailability, metabolism, and disposition. *J Toxicol Environ Health, Part A*, 54: 301-317.